<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">48378</article-id><article-id pub-id-type="doi">10.7554/eLife.48378</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Complement and CD4<sup>+</sup> T cells drive context-specific corneal sensory neuropathy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-141187"><name><surname>Royer</surname><given-names>Derek J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8476-1784</contrib-id><email>Derek.Royer@Duke.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-141561"><name><surname>Echegaray-Mendez</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141562"><name><surname>Lin</surname><given-names>Liwen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150252"><name><surname>Gmyrek</surname><given-names>Grzegorz B</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141563"><name><surname>Mathew</surname><given-names>Rose</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141564"><name><surname>Saban</surname><given-names>Daniel R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141572"><name><surname>Perez</surname><given-names>Victor L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135734"><name><surname>Carr</surname><given-names>Daniel JJ</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Ophthalmology</institution><institution>Duke University Medical Center</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Ophthalmology</institution><institution>University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Immunology</institution><institution>Duke University Medical Center</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Microbiology and Immunology</institution><institution>University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chiu</surname><given-names>Isaac M</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Ophthalmology, Duke Eye Center, Durham, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>08</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e48378</elocation-id><history><date date-type="received" iso-8601-date="2019-05-10"><day>10</day><month>05</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-08-15"><day>15</day><month>08</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Royer et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Royer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-48378-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary" xlink:href="10.7554/eLife.51497"/><abstract><object-id pub-id-type="doi">10.7554/eLife.48378.001</object-id><p>Whether complement dysregulation directly contributes to the pathogenesis of peripheral nervous system diseases, including sensory neuropathies, is unclear. We addressed this important question in a mouse model of ocular HSV-1 infection, where sensory nerve damage is a common clinical problem. Through genetic and pharmacologic targeting, we uncovered a central role for C3 in sensory nerve damage at the morphological and functional levels. Interestingly, CD4 T cells were central in facilitating this complement-mediated damage. This same C3/CD4 T cell axis triggered corneal sensory nerve damage in a mouse model of ocular graft-versus-host disease (GVHD). However, this was not the case in a T-dependent allergic eye disease (AED) model, suggesting that this inflammatory neuroimmune pathology is specific to certain disease etiologies. Collectively, these findings uncover a central role for complement in CD4 T cell-dependent corneal nerve damage in multiple disease settings and indicate the possibility for complement-targeted therapeutics to mitigate sensory neuropathies.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.48378.002</object-id><title>eLife digest</title><p>Most people have likely experienced the discomfort of an eyelash falling onto the surface of their eye. Or that gritty sensation when dust blows into the eye and irritates the surface. These sensations are warnings from sensory nerves in the cornea, the transparent tissue that covers the iris and pupil. Corneal nerves help regulate blinking, and control production of the tear fluid that protects and lubricates the eye.</p><p>But if the cornea suffers damage or infection, it can become inflamed. Long-lasting inflammation can damage the corneal nerves, leading to pain and vision loss. If scientists can identify how this happens, they may ultimately be able to prevent it. To this end, Royer et al. have used mice to study three causes of hard-to-treat corneal inflammation. The first is infection with herpes simplex virus (HSV-1), which also causes cold sores. The second is eye allergy, where the immune system overreacts to substances like pollen or pet dander. And the third is graft-versus-host disease (GVHD), an immune disorder that can affect people who receive a bone marrow transplant.</p><p>Royer et al. showed that HSV-1 infection and GVHD – but not allergies – made the mouse cornea less sensitive to touch. Consistent with this, microscopy revealed damage to corneal nerves in the mice with HSV-1 infection and those with GVHD. Further experiments showed that immune cells called CD4 T cells and a protein called complement C3 were contributing to this nerve damage. Treating the mice with an experimental drug derived from cobra venom protected the cornea from the harmful effects of inflammation. It did so by blocking activation of complement C3 at the eye surface.</p><p>Identifying factors such as complement C3 that are responsible for corneal nerve damage is an important first step in helping patients with inflammatory eye diseases. Many drugs that target the complement pathway are currently under development. Some of these drugs could potentially be adapted for delivery as eye drops. But first, experiments must test whether complement also contributes to corneal nerve damage in humans. If it does, work can then begin on testing these drugs for safety and efficacy in patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cornea</kwd><kwd>neuropathy</kwd><kwd>inflammation</kwd><kwd>HSV-1</kwd><kwd>graft vs. host disease</kwd><kwd>complement</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01 EY021238</award-id><principal-award-recipient><name><surname>Carr</surname><given-names>Daniel JJ</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>P30 EY021725</award-id><principal-award-recipient><name><surname>Carr</surname><given-names>Daniel JJ</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01 EY021798</award-id><principal-award-recipient><name><surname>Saban</surname><given-names>Daniel R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>R01 EY024484</award-id><principal-award-recipient><name><surname>Perez</surname><given-names>Victor L</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>P30 EY005722</award-id><principal-award-recipient><name><surname>Saban</surname><given-names>Daniel R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The complement pathway can contribute to corneal sensation loss and nerve damage during ocular surface inflammation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Dysregulated complement activation is increasingly recognized as a significant pathological event in a variety of neurodegenerative and neuroinflammatory diseases of the central nervous system (<xref ref-type="bibr" rid="bib115">Tenner et al., 2018</xref>). These include conditions from Alzheimer’s disease and age-related macular degeneration (AMD) to amyotrophic lateral sclerosis and multiple sclerosis (<xref ref-type="bibr" rid="bib45">Hong et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Knickelbein et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Loveless et al., 2018</xref>). Complement may orchestrate peripheral nervous system (PNS) disorders as well. For instance, nociceptive hypersensitivities, sensory neuropathies, and Guillain-Barré syndrome have been linked to aberrant complement activation (<xref ref-type="bibr" rid="bib90">Rosoklija et al., 2000</xref>; <xref ref-type="bibr" rid="bib85">Ramaglia et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Jang et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Fritzinger and Benjamin, 2016</xref>; <xref ref-type="bibr" rid="bib126">Xu et al., 2018</xref>; <xref ref-type="bibr" rid="bib111">Susuki et al., 2007</xref>). However, the mechanistic role of complement is not well understood in neuroinflammatory pathologies impacting the PNS. Moreover, the pathophysiological trigger of sensory fiber retraction which contributes to sensation loss and in some instances chronic pain is unclear (<xref ref-type="bibr" rid="bib108">Stepp et al., 2017</xref>). Available treatments for peripheral neuropathies primarily focus on clinical symptoms without addressing the underlying pathomechanisms (<xref ref-type="bibr" rid="bib15">Colloca et al., 2017</xref>). Accordingly, elucidation of relevant pathomechanisms underlying sensory neuropathies may translate into efficacious mechanism-based therapeutics.</p><p>The complement cascade is comprised of dozens of soluble and membrane-bound factors essential for host defense and efficient clearance of cellular debris. However, proper regulation of complement activation is necessary to balance immune responses and prevent collateral tissue damage (<xref ref-type="bibr" rid="bib88">Ricklin et al., 2016</xref>). The complement cascade pivots upon activation of complement component 3 (C3) for its downstream proinflammatory effects. The pathogenic contributions of complement in systemic disease have been reviewed extensively in recent years (<xref ref-type="bibr" rid="bib24">Dobó et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Hajishengallis et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">McGeer et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Ricklin et al., 2016</xref>). Nonetheless, emerging concepts centering on complement effector synthesis within inflamed tissue microenvironments have ushered in a ‘renaissance’ of novel complement-targeted drug development strategies (<xref ref-type="bibr" rid="bib89">Ricklin et al., 2018</xref>; <xref ref-type="bibr" rid="bib117">Tomlinson and Thurman, 2018</xref>). Therefore, elucidating whether the complement cascade is a viable therapeutic target in inflammation-associated peripheral nerve impairment remains medically important.</p><p>The eye has been labeled a ‘complement dysregulation hotspot’ due to complement’s contributions to many ophthalmic diseases, but complement activation is restricted in the healthy cornea (<xref ref-type="bibr" rid="bib13">Clark and Bishop, 2018</xref>). As observed in AMD, subtle inflammatory reactions in the eye can mediate significant visual morbidity. Accordingly, ocular inflammation is tightly regulated by various anatomic, physiologic, and immunologic mechanisms in order to maintain visual acuity (<xref ref-type="bibr" rid="bib2">Amouzegar et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Streilein, 2003</xref>; <xref ref-type="bibr" rid="bib113">Taylor et al., 2018</xref>). These homeostatic mechanisms, collectively dubbed ‘ocular immune privilege,’ help preserve the ocular surface and enable the cornea to properly focus incoming light onto the retina. Furthermore, corneal nerves are increasingly recognized as central regulators of immune privilege at the ocular surface (<xref ref-type="bibr" rid="bib36">Guzmán et al., 2018</xref>; <xref ref-type="bibr" rid="bib77">Neelam et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Paunicka et al., 2015</xref>). Consequently, inflammatory events that damage corneal nerves can have insidious consequences in terms of ocular surface health and transparency (<xref ref-type="bibr" rid="bib75">Müller et al., 2003</xref>; <xref ref-type="bibr" rid="bib106">Shaheen et al., 2014</xref>; <xref ref-type="bibr" rid="bib108">Stepp et al., 2017</xref>). One such pathway that can rapidly initiate inflammation following activation is the complement cascade. Corneal nerves originate predominantly from the ophthalmic branch of the trigeminal ganglion (TG), and these peripheral nerves provide the cornea with the highest density of sensory fibers in the human body. While the cornea and peripheral nerves constitutively synthesize complement proteins (<xref ref-type="bibr" rid="bib6">Bora et al., 2008</xref>; <xref ref-type="bibr" rid="bib22">de Jonge et al., 2004</xref>), the role of the complement cascade in corneal nerve damage has not been explored. Nonetheless, the complement pathway is poised for vigorous activation in the cornea in response to noxious or inflammatory stimuli (<xref ref-type="bibr" rid="bib6">Bora et al., 2008</xref>). Moreover, C3 activation has been reported in the cornea soon after infection with herpes simplex virus type 1 (HSV-1), which is a common cause of corneal sensory nerve damage in patients (<xref ref-type="bibr" rid="bib93">Royer et al., 2017</xref>; <xref ref-type="bibr" rid="bib99">Sacchetti and Lambiase, 2014</xref>). Given the cornea’s high density of sensory nerves, it is particularly amenable for investigating the mechanistic role of complement in peripheral nerve damage. To this end, we evaluated corneal nerve integrity and mechano-sensory function using a murine model of ocular HSV-1 infection to test the hypothesis that local complement activation and T cell engagement coordinate corneal nerve damage.</p><p>The pathobiology underlying non-penetrating corneal nerve damage is not well understood, although inflammation is generally recognized as an important feature (<xref ref-type="bibr" rid="bib77">Neelam et al., 2018</xref>; <xref ref-type="bibr" rid="bib106">Shaheen et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Cruzat et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Chucair-Elliott et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Chucair-Elliott et al., 2017b</xref>; <xref ref-type="bibr" rid="bib11">Chucair-Elliott et al., 2017a</xref>). While HSV-1 is a clinically prominent cause of corneal nerve damage and sensation loss, a variety of pathogenic microbes impair the corneal nerve architecture upon ocular infection (<xref ref-type="bibr" rid="bib20">Cruzat et al., 2015</xref>). This observation adds to evidence that the neurotropism of HSV-1 is not directly responsible for nerve damage (<xref ref-type="bibr" rid="bib10">Chucair-Elliott et al., 2016</xref>). In addition to sensation loss evoked by HSV-1, corneal nerve alterations in other contexts such as dry eye disease are associated with a broad array of neuropathic clinical symptoms including dryness, itch, and pain (<xref ref-type="bibr" rid="bib3">Andersen et al., 2017</xref>). To further qualify the possible role of complement in corneal nerve damage independent of infection, we evaluated corneal mechanosensory function in two noninfectious T cell-dependent ocular surface inflammatory diseases. For this purpose, we utilized established murine models of allergic eye disease (AED) and ocular graft-versus-host disease (GVHD) (<xref ref-type="bibr" rid="bib44">Herretes et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Lee et al., 2015</xref>). Our rationale for this is that complement has been implicated in the etiology of systemic GVHD and allergic inflammation (<xref ref-type="bibr" rid="bib34">Gour et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Kwan et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="bib78">Nguyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib130">Zhang and Köhl, 2010</xref>). However, a neuroinflammatory role of complement has not been described for either disease within the eye.</p><p>The translational relevance of this study is underscored by in vivo confocal microscopy data from multiple clinical studies showing architectural changes in the corneal nerves of patients with herpetic keratitis, chronic ocular allergy, and ocular GVHD (<xref ref-type="bibr" rid="bib38">Hamrah et al., 2010</xref>; <xref ref-type="bibr" rid="bib76">Müller et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Moein et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Hu et al., 2008</xref>; <xref ref-type="bibr" rid="bib54">Le et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Leonardi et al., 2012</xref>; <xref ref-type="bibr" rid="bib116">Tepelus et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">He et al., 2017a</xref>). Elucidating the pathomechanisms underlying corneal nerve damage may enable development of more effective therapeutics to mitigate progression of such ocular surface inflammatory diseases. Each of the animal models utilized herein mimic clinically important, chronic ocular surface morbidities. Herpes simplex virus type 1 (HSV-1) is a common cause of neurotropic keratitis and remains a leading cause of infectious corneal blindness (<xref ref-type="bibr" rid="bib99">Sacchetti and Lambiase, 2014</xref>; <xref ref-type="bibr" rid="bib30">Farooq and Shukla, 2012</xref>). The incidence of ocular allergy exceeds twenty percent of the population with varying degrees of neurogenic ocular surface discomfort that can severely diminish quality of life (<xref ref-type="bibr" rid="bib19">Craig et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Patel et al., 2017</xref>; <xref ref-type="bibr" rid="bib98">Saban et al., 2013</xref>). Finally, GVHD is the greatest cause of non-relapse morbidity following hematopoietic stem cell transplantation (HSCT) used to treat life-threatening malignancies and immunologic diseases (<xref ref-type="bibr" rid="bib67">MacDonald et al., 2017</xref>). A majority of patients with chronic presentations of GVHD suffer from ocular surface involvement (<xref ref-type="bibr" rid="bib107">Shikari et al., 2013</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>C3 facilitates corneal sensation loss in herpetic keratitis</title><p>Adaptive immunity has been shown to <italic>prevent</italic> recovery of corneal sensory function following ocular HSV-1 infection (<xref ref-type="bibr" rid="bib128">Yun et al., 2014</xref>), but the initial pathophysiological triggers of denervation and sensation loss are not definitively characterized. Ocular HSV-1 infection provokes corneal denervation and sensation loss between days 5 to 8 post-infection (p.i.) in immunologically naive C57BL/6 mice (<xref ref-type="bibr" rid="bib9">Chucair-Elliott et al., 2015</xref>). This tempo appears to be synchronized with the host transition from innate to adaptive immunity following infection. Indeed, corneal nerve fiber retraction was evident upon T cell infiltration in the cornea (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Accordingly, we hypothesized that local complement activation and T cell engagement coordinate corneal nerve damage during HSV-1 infection.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.003</object-id><label>Figure 1.</label><caption><title>Complement C3 contributes to corneal denervation.</title><p>(<bold>A</bold>) Representative confocal images of cornea flat-mounts showing corneal nerves (βIII Tubulin, white) and T cells (CD3, green) in healthy uninfected (UI) and HSV-1-infected corneas 8 days post infection (p.i.). (<bold>B</bold>) Corneal mechanosensory function in WT and C3<sup>-/-</sup> mice following ocular HSV-1 infection (<italic>n</italic> = 6–8 mice/group; three independent experiments). (<bold>C</bold>) Viral titers shed in the tear film of WT and C3<sup>-/-</sup> mice at the indicated times p.i. (<italic>n</italic> = 5 mice per group; two independent experiments). Viral titers in the corneas and trigeminal ganglia (TG) of WT and C3<sup>-/-</sup> mice are shown at days 3 and 7 p.i. in (<bold>D</bold>) and (<bold>E</bold>), respectively. (<bold>F</bold>) Representative confocal images of stromal nerve fibers and T cells in healthy and HSV-infected corneas of WT and C3<sup>-/-</sup> mice as in (<bold>A</bold>). (<bold>G</bold>) Flow cytometry-based quantification of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in HSV-infected corneas at day 7 p.i. (<italic>n</italic> = 7–8 mice/group; four independent experiments). Statistical differences were determined using two-way ANOVAs with Bonferroni posttests (<bold>B, C</bold>) or Student’s T tests (<bold>D, E, G</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>C3<sup>-/-</sup>mice retain corneal sensation through viral latency.</title><p>WT and C3<sup>-/-</sup> mice were infected with 1 × 10<sup>4</sup> p.f.u. HSV-1 McKrae per eye and corneal sensation thresholds measured at day 30 post infection when HSV-1 is considered to be latent in animal infection models (<italic>n</italic> = 6–12 eyes/group; Student’s T-test).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig1-figsupp1-v2.tif"/></fig></fig-group><p>To address our hypothesis, corneal sensation and pathogen burden were evaluated in C57BL/6 wildtype (WT) and complement C3-deficient (C3<sup>-/-</sup>) mice following ocular HSV-1 infection. Progressive loss of corneal mechano-sensitivity was evident in WT mice by days 5 to 8 p.i., but corneal sensation was conserved in the C3<sup>-/-</sup> cohort (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The same trend revealing preservation of corneal sensation in C3<sup>-/-</sup> animals was also observed with an increased HSV-1 challenge inoculum (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Viral titers were measured at time points before and after the onset of corneal sensation loss to determine whether the divergence in sensation stemmed from a differential susceptibility to infection. On day 3 p.i., the HSV-1 burden was similar in the tear film, corneas, and TG of WT and C3<sup>-/-</sup> animals (<xref ref-type="fig" rid="fig1">Figure 1C–D</xref>). By day 7 p.i., HSV-1 titers were elevated in the tear film and TG of C3<sup>-/-</sup> mice relative to WT (<xref ref-type="fig" rid="fig1">Figure 1C,E</xref>). Corneal buttons from WT mice exhibited extensive denervation with CD3<sup>+</sup> T cell infiltration at day 8 p.i. (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). However, T cell infiltration was observed without widespread denervation in C3<sup>-/-</sup> corneas (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The number of cornea-infiltrating CD4<sup>+</sup> or CD8<sup>+</sup> T cells were similar among WT and C3<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Together, these data indicate that corneal sensation loss in herpetic keratitis involves a C3-dependent inflammatory process independent of viral burden.</p></sec><sec id="s2-2"><title>Corneal sensation loss during HSV-1 infection requires T cell coordination</title><p>Although T cells successfully extravasate into the corneas of WT and C3<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1F,G</xref>), C3-deficiency can have broad impacts on T cell priming, clonal expansion, and recruitment (<xref ref-type="bibr" rid="bib14">Clarke and Tenner, 2014</xref>; <xref ref-type="bibr" rid="bib124">West et al., 2018</xref>). To investigate this possibility, corneas from HSV-1-infected WT and C3<sup>-/-</sup> mice were evaluated for chemokines associated with T cell recruitment, and the eye-draining mandibular lymph nodes (MLN) were harvested to evaluate T cell responses. Chemokines associated with T cell recruitment were elevated in corneas from both WT and C3<sup>-/-</sup> mice at day 5 p.i.—a time consistent with onset of sensation loss (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Moreover, CD4<sup>+</sup> and CD8<sup>+</sup> T cell expansion was comparable within the eye-draining mandibular lymph nodes (MLN) from WT and C3<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Similarly, T cells harvested from WT and C3<sup>-/-</sup> mice at day 8 p.i. responded equally to in vitro stimulation in terms of IFNγ production (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Collectively, these data show that C3<sup>-/-</sup> T cells exhibit normal expansion and recruitment to the cornea during ocular HSV-1 infection.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.005</object-id><label>Figure 2.</label><caption><title>T cells facilitate corneal sensation loss.</title><p>(<bold>A</bold>) Chemokine concentrations in HSV-1-infected corneas from WT and C3<sup>-/-</sup> mice at day five post infection (p.i.). (<bold>B</bold>) T cell expansion in the eye-draining mandibular lymph nodes of WT and C3<sup>-/-</sup> mice. For panels (<bold>A</bold>) and (<bold>B</bold>), dashed lines reflect the average value for uninfected WT controls (<italic>n</italic> = 5 mice per group; two independent experiments; Student’s T). (<bold>C</bold>) IFNγ expression following stimulation with PMA and ionomycin using T cells harvested from WT or C3<sup>-/-</sup> mice at day eight post infection (<italic>n</italic> = 7 unstimulated and 10 activated replicates from three independent experiments; one-way ANOVA, Bonferroni). (<bold>D</bold>) Adoptive transfer schematic and corneal sensation measurements in TCRα<sup>-/-</sup> mice following reconstitution with purified splenic T cells from HSV-infected WT and C3<sup>-/-</sup> mice (<italic>n</italic> = 5–9 TCRα<sup>-/-</sup> mice/group; three independent experiments; two-way ANOVA, Bonferroni).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.006</object-id><label>Figure 2—figure supplement 1.</label><caption><title>T cell engraftment in recipient TCRα<sup>-/-</sup> mice.</title><p>(<bold>A</bold>) T cell reconstitution was confirmed by evaluating the total number of T cells in the eye-draining mandibular lymph nodes of HSV-1-infected TCRα<sup>-/-</sup> mice. (<bold>B</bold>) Impact of exogenous T cell reconstitution in TCRα<sup>-/-</sup> mice as determined by HSV-1 titers in the trigeminal ganglia (TG). Data reflect summaries of 5–9 mice/group across three independent experiments (one-way ANOVA, Bonferroni).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig2-figsupp1-v2.tif"/></fig></fig-group><p>In support of our hypothesis that C3 and T cells jointly coordinate corneal sensation loss, frank corneal sensation loss was not observed following ocular HSV-1 infection in C3-sufficient, alpha-beta T cell receptor-deficient mice (TCRα<sup>-/-</sup>) which congenitally lack classical CD4<sup>+</sup> and CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). To investigate potential functional defects of C3<sup>-/-</sup> T cells in an in vivo context, CD3<sup>+</sup> T cells were harvested from HSV-infected WT or C3<sup>-/-</sup> mice at day 8 p.i. and adoptively transferred into TCRα<sup>-/-</sup> mice. Six days following cell transfer, TCRα<sup>-/-</sup> recipients were infected with HSV-1 and corneal sensation monitored longitudinally. Adoptive transfer of CD3<sup>+</sup> T cells from either WT or C3<sup>-/-</sup> donors evoked progressive corneal sensation loss in TCRα<sup>-/-</sup> recipients by day 8 p.i. (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These findings further corroborate that C3<sup>-/-</sup> T cells remain functional in vivo. Analysis of corneal sensation was not feasible beyond 8 days p.i., as the TCRα<sup>-/-</sup> mice succumbed to herpetic encephalitis. However, engraftment of donor cells was confirmed by analysis of T cells in the eye-draining MLN of recipient mice by flow cytometry at day 8 p.i. The baseline lymphocyte counts in MLN from TCRα<sup>-/-</sup> controls likely reflect expansion of non-classical T cell populations (<xref ref-type="bibr" rid="bib121">Viney et al., 1994</xref>). An increase in total cell number was observed for CD4<sup>+</sup> but not CD8<sup>+</sup> T cells upon adoptive transfer of purified CD3<sup>+</sup> T cells into TCRα<sup>-/-</sup> recipient mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Consistent with this observation, our data show that transfer of CD3<sup>+</sup> T cells from HSV-infected mice have no appreciable impact on HSV-1 titers in the TG of TCRα<sup>-/-</sup> recipients by day 8 p.i. (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Notably, bulk transfer of HSV-specific CD8<sup>+</sup> T cells has been shown to reduce viral burden in the peripheral nervous system of C57BL/6 mice during acute HSV-1 infection (<xref ref-type="bibr" rid="bib16">Conrady et al., 2009</xref>; <xref ref-type="bibr" rid="bib92">Royer et al., 2016</xref>). Our collective findings reveal that C3 and T cells are individually necessary and interdependent in the pathogenesis of HSV-1-associated corneal sensation loss. Whether by direct or indirect mechanisms, these data support a paradigm in which C3 activation and T cell engagement coordinate corneal nerve damage in herpetic keratitis.</p></sec><sec id="s2-3"><title>Antigen-specific CD4<sup>+</sup> T cells facilitate corneal sensation loss in HSV-1 keratitis</title><p>Our data show that T cells contribute to corneal sensation loss during acute HSV-1 infection, yet whether this pathology is dependent upon CD4<sup>+</sup> or CD8<sup>+</sup> T cells remained unclear. To better discern the contributions of each subset, CD4<sup>+</sup> and CD8<sup>+</sup> T cells were harvested from infected WT mice, transferred into separate groups of TCRα<sup>-/-</sup> mice, and recipient mice subsequently infected with HSV-1. Corneal sensation loss during acute HSV-1 infection was only observed upon reconstitution with CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Donor cell engraftment was confirmed by flow cytometry, although a statistically significant increase in cell number within the eye-draining MLN was only observed upon transfer of CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The requirement for antigen specificity was subsequently evaluated during acute HSV-1 infection by monitoring corneal sensation in WT and OT-II transgenic mice that generate ovalbumin (OVA)-specific CD4 T cells. Transgenic OT-II mice did not exhibit corneal sensation loss following infection despite evidence of bystander CD4<sup>+</sup> T cell activation and recruitment into the cornea (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Adoptive transfer of CD4<sup>+</sup> T cells from HSV-infected WT and OT-II mice into TCRα<sup>-/-</sup> recipients corroborated these findings (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Abrasion of the corneal epithelium, which is required to mediate infection in this model, induces local chemokine expression capable of recruiting T cells to the cornea even in the absence of viral infection (<xref ref-type="bibr" rid="bib60">Liu et al., 2012</xref>). Nonetheless, active corneal HSV-1 infection was necessary to provoke corneal sensation loss, as TCRα<sup>-/-</sup> mice reconstituted with CD4<sup>+</sup> T cells harvested from HSV-infected WT mice did not elicit auto/allo-antigen-associated sensation loss within two weeks of corneal scratch injury (i.e. mock infection) (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Collectively, our data show that complement C3 and antigen-specific CD4<sup>+</sup> T cells are simultaneously necessary to drive corneal sensation loss during HSV-1 infection. These results strongly portend that a coordinated inflammatory axis exists involving C3 and antigen-specific CD4<sup>+</sup> T cells, and that it is responsible for sensory neuropathy in herpetic keratitis.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.007</object-id><label>Figure 3.</label><caption><title>Antigen-specific CD4 T cells drive corneal sensation loss.</title><p>(<bold>A</bold>) Adoptive transfer schematic and corneal sensation measurements in TCRα<sup>-/-</sup> mice following reconstitution with purified splenic CD4 or CD8 T cells from HSV-infected WT mice (<italic>n</italic> = 6–7 TCRα<sup>-/-</sup> mice/group; two independent experiments; two-way ANOVA, Bonferroni). (<bold>B</bold>) Corneal sensation measurements at baseline and day seven post infection (p.i.) in WT and OT-II mice following ocular HSV-1 infection (<italic>n</italic> = 4–6 mice/group; three independent experiments). (<bold>C</bold>) Percentage of CXCR3-expressing CD4 T cells in peripheral blood from WT and OT-II mice at day 7 p.i.; (<italic>n</italic> = 5 mice/group; two independent experiments). (<bold>D</bold>) Verification of CD4 T cell infiltration into corneas of WT and OT-II mice at day 7 p.i. (<italic>n</italic> = 3 mice/group; two independent experiments). Data in panels B-D were analyzed using Student’s T tests.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.008</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Engraftment of donor T cells into TCRα<sup>-/-</sup> mice.</title><p>T cell reconstitution was confirmed by evaluating the total number of T cells in the eye-draining mandibular lymph nodes (MLN) of HSV-1-infected TCRα<sup>-/-</sup> mice by flow cytometry 8 days post HSV-1 infection (<italic>n</italic> = 6–7 TCRα<sup>-/-</sup> mice/group; two independent experiments; one-way ANOVA, Bonferroni).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.009</object-id><label>Figure 3—figure supplement 2.</label><caption><title>Antigen-specific donor CD4 T cells drive sensation loss during HSV-1 keratitis.</title><p>Adoptive transfer schematic and corneal sensation measurements at baseline and day seven post infection in HSV-1-infected TCRα<sup>-/-</sup> mice following reconstitution with purified splenic CD4 T cells from HSV-infected WT or OT-II mice (<italic>n</italic>= 5 TCRα<sup>-/-</sup> mice/group; two independent experiments; one-way ANOVA comparing each timepoint, Bonferroni posttest).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.010</object-id><label>Figure 3—figure supplement 3.</label><caption><title>Active corneal HSV-1 infection is required to drive sensation loss in herpetic keratitis.</title><p>Corneal sensation in TCRα<sup>-/-</sup> mice following reconstitution with purified CD4 T cells from HSV-1 infected WT mice as in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, with recipient TCRα<sup>-/-</sup> mice undergoing mock infection (corneal scratch injury). T cell engraftment was confirmed by flow cytometry using MLN from TCRα<sup>-/-</sup> mice 14 days after mock infection (<italic>n</italic> = 3–5 TCRα<sup>-/-</sup> mice/group; two independent experiments; two-way ANOVA, Student’s T test).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig3-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Nonhematopoietic cornea-resident cells and CSF1R<sup>+</sup> leukocytes augment local C3 synthesis during herpetic keratitis</title><p>Complement-mediated tissue pathology can arise from complement activators synthesized by the liver (systemic complement) or in tissue microenvironments (local complement). While local complement activation and regulation have been reported in the cornea in health and disease (<xref ref-type="bibr" rid="bib5">Bora et al., 1993</xref>; <xref ref-type="bibr" rid="bib13">Clark and Bishop, 2018</xref>; <xref ref-type="bibr" rid="bib73">Mondino and Brady, 1981</xref>; <xref ref-type="bibr" rid="bib119">Verhagen et al., 1992</xref>), the expression profile and cellular sources of various complement components have not been investigated in the context of ocular HSV-1 infection. To this end, a modest array of complement component transcripts was evaluated by semiquantitative real-time PCR on corneal buttons from healthy and HSV-infected mice at day 2 and 7 p.i. Upregulation of complement effectors and anaphylatoxin receptors were noted including <italic>C3</italic>, <italic>C5</italic>, <italic>C3ar1</italic>, and <italic>C5ar1</italic> (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). Constitutive expression of complement receptor 2 (CD21) has been reported in the corneal epithelium (<xref ref-type="bibr" rid="bib58">Levine et al., 1990</xref>), but variances in its expression during HSV-1 infection were not statistically significant across the time points evaluated (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Likewise, no differences in the local expression of various complement regulators were observed in HSV-infected corneas aside from the C1-inhibitor <italic>SerpinG1</italic> (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Collectively, this expression profile favors local complement activation, as effectors are upregulated without proportional enhancement of pathway regulatory components.</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.011</object-id><label>Figure 4.</label><caption><title>Corneal HSV-1 infection enhances local complement synthesis.</title><p>Gene expression of complement effectors (<bold>A</bold>), receptors (<bold>B</bold>), and regulators (<bold>C</bold>) upregulated in the corneas of B6 mice during acute HSV-1 infection (n = 7 WT mice/group; two independent experiments; Kruskal-Wallis, Dunn’s multiple comparisons test). (<bold>D</bold>) Relative <italic>C3</italic> expression among selected cornea-resident and infiltrating cell subsets at day three post-infection (<italic>n</italic> = 3–4 pooled samples from two mice each for cell subsets or three independent cornea pairs; two independent experiments; one-way ANOVA, Bonferroni; ND, not detected/amplification cycle &gt;35). Final PCR products were resolved on an agarose gel to verify amplification. Data are relative to GAPDH expression and normalized to uninfected control samples for panels A-C or to purified CSF1R-expressing peripheral blood monocytes/macrophages in panel D.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig4-v2.tif"/></fig><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.012</object-id><label>Table 1.</label><caption><title>Complement regulatory factor expression in the cornea during HSV-1 infection</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Gene</th><th valign="top">Uninfected</th><th valign="top">Day 2 p.i.</th><th valign="top">Day 7 p.i.</th></tr></thead><tbody><tr><td valign="top"><italic>C4bp</italic></td><td valign="top">ND</td><td valign="top">ND</td><td valign="top">ND</td></tr><tr><td valign="top"><italic>Crry (CD46 homolog)</italic></td><td valign="top">1.193 ± 0.338</td><td valign="top">0.817 ± 0.172</td><td valign="top">1.137 ± 0.331</td></tr><tr><td valign="top"><italic>CD55 (DAF)</italic></td><td valign="top">1.087 ± 0.201</td><td valign="top">1.035 ± 0.199</td><td valign="top">0.791 ± 0.251</td></tr><tr><td valign="top"><italic>CD59a (MIRL)</italic></td><td valign="top">1.078 ± 0.192</td><td valign="top">0.611 ± 0.123</td><td valign="top">0.728 ± 0.191</td></tr><tr><td valign="top"><italic>Cfi</italic></td><td valign="top">ND</td><td valign="top">ND</td><td valign="top">ND</td></tr><tr><td valign="top"><italic>Cr1l</italic></td><td valign="top">1.026 ± 0.096</td><td valign="top">0.7442 ± 0.222</td><td valign="top">0.889 ± 0.133</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean ± SEM; <italic>n</italic> = 7 samples/group. Gene expression is standardized to internal <italic>GAPDH</italic> expression and relative to uninfected control tissue<sc>.</sc> Abbreviations: C4bp, C4 binding protein; CD, cluster of differentiation; Cfi, complement factor I, Cr1l, complement C3b/C4b receptor-1-like; DAF, decay accelerating factor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MIRL, membrane inhibitor of reactive lysis; ND, not detected (amplification cycle &gt;35); p.i., post-infection.</p></fn></table-wrap-foot></table-wrap><p>As C3 is the central component of the complement activation pathway, the cellular sources of complement C3 were evaluated in corneas infected with HSV-1. Monocytes and tissue macrophages are known sources of C3 (<xref ref-type="bibr" rid="bib28">Einstein et al., 1977</xref>; <xref ref-type="bibr" rid="bib63">Lubbers et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Morgan and Gasque, 1997</xref>; <xref ref-type="bibr" rid="bib120">Verschoor et al., 2001</xref>), thus CSF1R<sup>+</sup> cells from the peripheral blood of transgenic CSF1R-GFP mice (MAFIA) were utilized as the relative standard for <italic>C3</italic> transcript expression. Expression of <italic>C3</italic> was noted in CD45<sup>+</sup> leukocytes isolated from infected corneas, yet detection of <italic>C3</italic> expression was lost when CSF1R<sup>+</sup> cells were removed from the total CD45<sup>+</sup> pool. In addition, isolated EpCAM<sup>+</sup> corneal epithelial cells expressed <italic>C3</italic> at levels comparable to blood monocytes. However, the <italic>C3</italic> expression level was greater in whole-cornea preparations than among individual cell fractions (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Taken together, our data show that both tissue-resident non-hematopoietic cells and resident/infiltrating CSF1R<sup>+</sup> leukocytes contribute to local <italic>C3</italic> expression in the cornea during acute HSV-1 infection.</p></sec><sec id="s2-5"><title>Localized pharmacologic C3 depletion preserves corneal sensation in HSV-1 keratitis</title><p>Ocular HSV-1 infection amplifies local complement gene expression, yet whether local control of complement activation can be harnessed to prevent corneal nerve damage has not been explored. From a clinical perspective, modulating complement activation at the ocular surface may be a viable therapeutic option. As a proof of concept, daily ocular cobra venom factor (CVF) treatment was explored as a putative method to deplete C3 and preserve corneal sensation during acute HSV-1 infection. Vehicle (PBS)-treated mice exhibited corneal sensation loss following HSV-1 infection, but CVF treatment preserved corneal sensation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Protein levels of C3 remained near baseline in the cornea following CVF treatment during HSV-1 infection, yet vehicle-treated animals exhibited a 300–600% increase in C3 protein levels in the cornea at days 3 and 7 p.i. (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Ocular CVF treatment did not significantly impact systemic serum C3 concentrations throughout the study (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.013</object-id><label>Figure 5.</label><caption><title>Local C3 depletion prevents HSV-associated corneal sensation loss.</title><p>B6 mice were given PBS (vehicle) or 5.0 μg cobra venom factor (CVF) via subconjunctival injection to degrade C3, and ocularly infected with HSV-1 18 hr later. C3 depletion was maintained by daily topical treatment (eyedrop) containing 0.5 μg CVF. (<bold>A</bold>) Corneal sensation following HSV-1 infection in animals treated with CVF or PBS (<italic>n</italic> = 5–11 mice/group; three independent experiments; two-way ANOVA, Bonferroni). Impact of CVF treatment on C3 protein concentrations in the cornea (<bold>B</bold>) and serum (<bold>C</bold>) (<italic>n</italic>= 3 cornea pairs, 5–9 serum samples/timepoint; 2–3 independent experiments; one-way ANOVA, Tukey). (<bold>D</bold>) Corneal edema measurements (central corneal thickness) determined via spectral domain optical coherence tomography (SD-OCT) on uninfected (UI) or HSV-1 infected mice treated with CVF or PBS at day 5 p.i. (<italic>n</italic> = 4–5 mice/group; two experiments; one-way ANOVA, Newman-Keuls). (<bold>E</bold>) Impact of CVF treatment on total leukocyte (CD45+) and monocyte/macrophage (CSF1R<sup>+</sup>) infiltration into the corneas of CVF and PBS-treated MaFIA (CSF1R-GFP) mice at day 3 p.i. (<italic>n</italic> = 5–6 mice/group; two independent experiments; Student’s T). (<bold>F</bold>) Representative flow plots showing cell populations in healthy and HSV-1 corneas from panel E. (<bold>G</bold>) Impact of CVF treatment on leukocyte infiltration into the corneas of HSV-1 infected mice at day 7 p.i. (<italic>n</italic> = 4–5 mice/group; two independent experiments; Student’s T). Note: Total CD45+ graph in panel G reflects data from two technical replicates. Dashed lines in panels E and G reflect cell number recorded in healthy uninfected mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.014</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Impact of ocular cobra venom factor treatment on HSV-1 titers.</title><p>The ocular surface of B6 mice was treated with PBS or CVF and animals ocularly infected with HSV-1 as in <xref ref-type="fig" rid="fig5">Figure 5</xref>. Systemic effects of CVF treatment were evaluated in terms of viral burden in the corneas and trigeminal ganglia (TG) at days 3 (<bold>A</bold>) and 7 (<bold>B</bold>) post infection (p.i.). Data in reflect three cornea pairs and 8–9 TG specimens per timepoint; data are composite from two independent experiments and analyzed using Student’s T tests.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.015</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Immunologic impacts of ocular cobra venom factor treatment.</title><p>The ocular surface of B6 mice was treated with PBS or CVF and animals ocularly infected with HSV-1 as in <xref ref-type="fig" rid="fig5">Figure 5</xref>. Immunologic impact of CVF treatment was assessed by flow cytometry on the eye-draining mandibular lymph nodes (MLN) (<bold>A</bold>) to assess CD4<sup>+</sup>, CD8<sup>+</sup>, and HSV-1 glycoprotein B (gB)-specific CD8<sup>+</sup> T cell numbers or blood (<bold>B</bold>) to evaluate CD4 count and percentage of activated (CXCR3<sup>+</sup>) CD4 T cells at day 7 p.i. Data in panel A reflects 6–8 mice/group; panel B reflects five samples/group; data are composite from two independent experiments and analyzed using Student’s T tests.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig5-figsupp2-v2.tif"/></fig></fig-group><p>Ocular CVF treatment limited corneal edema during HSV-1 infection relative to the vehicle control (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Consistent with this observation, CVF-treated animals had less leukocytic infiltrate (CD45<sup>+</sup>) into the cornea at day 3 p.i. and, specifically, fewer infiltrating CSF1R<sup>+</sup> cells (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>). By day 7 p.i., no difference in total CD45<sup>+</sup> or CSF1R<sup>+</sup> cells were observed in the cornea, yet there was a reduction in the total number of infiltrating CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Despite the difference in CSF1R<sup>+</sup> cell infiltration into the corneas at day 3 p.i., HSV-1 titers were similar in the corneas and TG comparing vehicle- and CVF-treated animals (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). By day 7 p.i. CVF-treated animals had less virus in the corneas and TG than vehicle controls (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), suggesting that CVF may have unexpected antiviral effects. However, CVF treatment did not have any discernable impact on T cell expansion in the eye-draining MLN or the total number of circulating CXCR3<sup>+</sup> CD4<sup>+</sup> T cells in HSV-1 infected animals (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Collectively, these findings imply that complement-targeted therapeutics could be tailored for ophthalmic use to limit tissue inflammation and preserve corneal sensation.</p></sec><sec id="s2-6"><title>Corneal sensation in other T cell-dependent ocular surface inflammatory diseases</title><p>While complement C3 and antigen-specific CD4<sup>+</sup> T cells appear to coordinate corneal sensation loss in herpetic keratitis, it remained to be determined whether this phenomenon was specific to HSV-1 infection. To this end, corneal sensation was measured independent of infection in two T cell-dependent ocular surface inflammatory diseases. Murine models of allergic eye disease (AED) and ocular graft-versus-host disease (GVHD) were employed to further delineate the hypothesized role of T cells in coordinating corneal nerve damage (<xref ref-type="bibr" rid="bib44">Herretes et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Lee et al., 2015</xref>). First, AED was induced using an established systemic ovalbumin (OVA)-sensitization and ocular challenge model (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) mimicking aspects of chronic keratoconjunctivitis (<xref ref-type="bibr" rid="bib1">Ahadome et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Lee et al., 2015</xref>). Clinical signs of ocular allergy developed as anticipated in OVA-challenged mice (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), yet corneal sensation loss was not observed (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Consistent with development of AED, corneas from OVA-challenged mice exhibited CD3<sup>+</sup> T cell infiltration by challenge day 7 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). However, frank corneal nerve loss was not observed in AED (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Morphometric analysis of confocal image stacks confirmed the preservation of corneal nerve density during AED (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), although CD3<sup>+</sup> T cell numbers were elevated in sensitized animals relative to healthy controls (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Flow cytometry was used to verify that the cornea-infiltrating T cells were predominately CD4<sup>+</sup> in the AED model (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Although clinical data show that corneal nerve remodeling can occur in patients with chronic ocular allergy (<xref ref-type="bibr" rid="bib46">Hu et al., 2008</xref>; <xref ref-type="bibr" rid="bib54">Le et al., 2011</xref>), allergy symptoms were not accompanied by frank loss of corneal mechano-sensation in the AED animal model.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.016</object-id><label>Figure 6.</label><caption><title>Chronic ocular allergy does not provoke frank corneal sensation loss.</title><p>(<bold>A</bold>) Schematic of allergic eye disease induced by ovalbumin (OVA) immunization followed by topical ocular OVA challenge. Healthy and OVA-challenged B6 mice were evaluated for signs of ophthalmic allergy (<bold>B</bold>) and corneal sensation thresholds (<bold>C</bold>). (<bold>D</bold>) Representative confocal images of cornea flat mounts from healthy and OVA-challenged mice showing nerves (βΙII Tubulin, red) and infiltrating T cells (CD3, green) in the central cornea at 20x magnification (scale bar = 100 μm). (<bold>E</bold>) Morphometric analysis of nerve densities in the central cornea based on confocal images. Normalization is based on the average volume in the healthy control group. (<bold>F</bold>) Quantification of total CD3<sup>+</sup> cells per field of view. (<bold>G</bold>) Flow cytometry was used to confirm CD4 T cell infiltration into the corneas of OVA-challenged mice. Data in panels B – F reflect 5 to 6 mice per group; flow plots in panel G reflect pooled digests of corneas from three mice. Data in panels E and F were analyzed using Student’s T tests.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig6-v2.tif"/></fig><p>Corneal sensation was also evaluated in a T cell-dependent allogeneic model of chronic GVHD with systemic and ocular manifestations following hematopoietic stem cell (HSC) transplantation (<xref ref-type="bibr" rid="bib82">Perez et al., 2016</xref>). This minor histocompatibility antigen mismatch model was established by transferring HSC-rich bone marrow (BM) and purified T cells from C57BL/6 (H2b) donors into lethally irradiated sex-matched C3.SW-H2b recipients. Recipient controls that receive BM without T cells recover and do not develop GVHD (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Onset of GVHD was established by transfer of BM with CD4<sup>+</sup> T cells only, CD8<sup>+</sup> T cells only, or both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Progressive corneal sensation loss was observed following transfer of CD4<sup>+</sup> T cells with and without addition of CD8<sup>+</sup> T cells. Addition of CD8<sup>+</sup> T cells alone evoked a transient corneal sensation deficit that recovered by day 26 post-transplant. However, corneal sensation loss was not observed in the BM only control group (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). External signs of ocular disease (see <xref ref-type="table" rid="table2">Table 2</xref>) were also apparent in groups receiving CD4<sup>+</sup> T cells by the study endpoint (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). The presence of tissue-infiltrating CD3<sup>+</sup> T cells in corneas from animals with GVHD was verified by confocal microscopy at the study endpoint. Consistent with sensation loss, corneal nerve integrity was markedly reduced in groups receiving CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Morphometric analysis of confocal image stacks confirmed the CD4-dependent decrease in corneal nerve density (<xref ref-type="fig" rid="fig7">Figure 7E</xref>) and concomitant increase in total CD3<sup>+</sup> cells (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Taken together, our data show for the first time that corneal sensation loss occurs early in ocular GVHD and that this pathology is instigated in part by allogeneic CD4<sup>+</sup> T cells.</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.017</object-id><label>Figure 7.</label><caption><title>CD4 T cells drive corneal sensation loss in ocular GVHD.</title><p>(<sc><bold>A</bold></sc>) Schematic of GVHD induction using T cell depleted bone marrow (TCD-BM) or TCD-BM with splenic T cells isolated from C57BL/6 donors and transferred into C3.SW-H2 b recipients. (<bold>B</bold>) Corneal sensation measurements in C3.SW-H2 b mice following reconstitution with BM only or with BM and 1.3x10 6 CD4, CD8, or CD4 and CD8 T cells. (<bold>C</bold>) External photographs showing CD4-dependent ocular surface morbidities consistent with corneal sensation loss. (<bold>D</bold>) Representative confocal images of cornea flat mounts from each group of mice at the study endpoint showing nerves (βΙII Tubulin, red) and infiltrating T cells (CD3, green) in the central cornea at 20x magnification (scale bar = 100 μm). (<bold>E</bold>) Morphometric analysis of nerve densities based on confocal images. Normalization is based on the average volume in the BM only control group. (<bold>F</bold>) Quantification of total CD3 + cells per field of view. Data reflect independent measurements of corneas from 3-4 mice per group across 2 experiments; sensation data were evaluated by two-way ANOVA with Bonferroni posttests; data in panels E and F were analyzed by one-way ANOVA with Bonferroni posttests. Figure was generated using Servier Medical Art (<ext-link ext-link-type="uri" xlink:href="http://smart.servier.com/">http://smart.servier.com/</ext-link>) under a Creative Commons 3.0 license.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig7-v2.tif"/></fig><table-wrap id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.018</object-id><label>Table 2.</label><caption><title>Ophthalmic Disease Scoring Guide for Ocular GVHD.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"><italic>Criteria</italic></th><th valign="top"><italic>Grade 0</italic></th><th valign="top"><italic>Grade 1</italic></th><th valign="top"><italic>Grade 2</italic></th><th valign="top"><italic>Grade 3</italic></th></tr></thead><tbody><tr><td valign="top">Eyelid Closure</td><td valign="top">None</td><td valign="top">Mild squinting</td><td valign="top">Partial lid closure</td><td valign="top">Full lid closure</td></tr><tr><td valign="top">Blepharitis</td><td valign="top">None</td><td valign="top">Mild lid margin edema</td><td valign="top">Moderate lid margin edema with crusting</td><td valign="top">Gross lid edema, loss of lashes/eyelid fur</td></tr><tr><td valign="top">Meibomian Gland Disease</td><td valign="top">None</td><td valign="top">≤4 plugs</td><td valign="top">&gt;4 plugs OR cystic plugs</td><td valign="top">&gt;4 plugs AND cystic plugs</td></tr><tr><td valign="top">Conjunctival <break/>Chemosis</td><td valign="top">None</td><td valign="top">Mild edema</td><td valign="top">Moderate edema</td><td valign="top">Gross edema</td></tr><tr><td valign="top">Conjunctival Hyperemia</td><td valign="top">None</td><td valign="top">Mild redness</td><td valign="top">Broad erythema</td><td valign="top">N/A</td></tr><tr><td valign="top">Mucoid Discharge</td><td valign="top">None</td><td valign="top">Mild discharge</td><td valign="top">Discharge covers the ocular surface</td><td valign="top">N/A</td></tr><tr><td valign="top">Corneal Opacity</td><td valign="top">None</td><td valign="top">Epithelial haze</td><td valign="top">Focal opacities</td><td valign="top">Widespread opacity</td></tr></tbody></table></table-wrap></sec><sec id="s2-7"><title>Localized pharmacologic C3 depletion preserves corneal sensation in ocular GVHD</title><p>The pharmacologic impact of local CVF treatment on ocular GVHD progression was consequently explored in order to identify whether the CD4<sup>+</sup> T cell-associated corneal sensation loss observed in both herpetic keratitis and ocular GVHD shared a common C3-codependent pathomechanism. For these experiments, GVHD was established in C3.SW-H2b recipients by transfer of C57BL/6-derived BM and CD3<sup>+</sup> T cells. Recipients from the BM only control and GVHD cohorts received ophthalmic treatment with either PBS or CVF (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Systemic disease progressed equally in both GVHD cohorts regardless of treatment (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Although CVF administration was limited to the eye, systemic serum C3 concentrations were lower in the GVHD cohort treated with CVF compared to the PBS-treated GVHD groups at the study endpoint. Nonetheless, the inverted CD4:CD8 T cell ratio (<xref ref-type="bibr" rid="bib44">Herretes et al., 2015</xref>) in the spleens and eye-draining mandibular lymph nodes of both groups of GVHD mice confirmed the presence of systemic disease (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Despite development of systemic disease, local CVF treatment preserved corneal nerve integrity and mechano-sensory function in ocular GVHD (<xref ref-type="fig" rid="fig8">Figure 8E,F</xref>). Morphometric analysis of confocal image stacks from the study endpoint corroborated the preservation of corneal nerve density in CVF-treated mice from the GVHD cohort (<xref ref-type="fig" rid="fig8">Figure 8G</xref>), although CVF did not reduce the number of total CD3<sup>+</sup> cells during GVHD relative to PBS (<xref ref-type="fig" rid="fig8">Figure 8H</xref>). In addition, CVF treatment also limited GVHD-associated periocular disease in female but not in male mice (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). In summary, these preclinical models establish that CD4<sup>+</sup> T cells and complement C3 coordinate corneal sensory nerve damage in both herpetic keratitis and ocular GHVD. Moreover, our data provide a proof of principle that complement-targeted therapeutics may limit the severity of immune-mediated sensory nerve damage at the ocular surface.</p><fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.48378.019</object-id><label>Figure 8.</label><caption><title>Local C3 depletion prevents corneal sensation loss in ocular GVHD.</title><p>(<bold>A</bold>) Experiment schematic of GVHD induction using T cell depleted bone marrow (TCD-BM) or TCD-BM with splenic T cells isolated from C57BL/6 donors and transferred into C3.SW-H2 b recipients. Each group was subsequently given a subconjunctival injection containing PBS (vehicle) or 5.0 μg cobra venom factor (CVF) to degrade C3. C3 depletion was maintained by topical treatment (eyedrop) containing 2.0 μg CVF twice weekly. (<bold>B</bold>) Systemic disease scores in each cohort (n=8 mice per group; two-way ANOVA, Bonferroni). (<bold>C</bold>) Impact of CVF treatment on serum C3 protein concentrations in each group at the experiment endpoint (n=5-6 samples/group; one-way ANOVA, Bonferroni). (<bold>D</bold>) Evaluation of CD4:CD8 ratios in secondary lymphoid organs by flow cytometry to confirm onset of GVHD at experimental endpoints (n=3-8 mice/group; 2 independent experiments; one-way ANOVA, Bonferroni). (<bold>E</bold>) Longitudinal corneal sensation measurements in each group of C3.SW-H2 b mice. (<bold>F</bold>) Representative confocal images of cornea flat mounts from each group of C3.SW-H2 b mice at the study endpoint showing nerves (βΙII Tubulin, red) and infiltrating T cells (CD3, green) in the central cornea at 20x magnification (scale bar = 100 μm). (<sc><bold>G</bold></sc>) Morphometric analysis of nerve densities based on confocal images. Normalization is based on the average volume in the BM only control group. (<bold>H</bold>) Quantification of total CD3 + cells per field of view. Data in panels E – H reflect 3-8 mice/group; 2 independent experiments; two-way ANOVA with Bonferroni posttests. Figure was generated using Servier Medical Art (<ext-link ext-link-type="uri" xlink:href="http://smart.servier.com/">http://smart.servier.com/</ext-link>) under a Creative Commons 3.0 license.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.48378.020</object-id><label>Figure 8—figure supplement 1.</label><caption><title>Sex-biased effects of local C3 depletion on ocular GVHD severity.</title><p>Models of GVHD were established as described in <xref ref-type="fig" rid="fig8">Figure 8</xref> with cohorts of bone marrow (BM) only controls and GVHD (BM + T cells) mice exposed to ocular treatment with PBS (vehicle) or cobra venom factor (CVF) to degrade complement C3. (<bold>A</bold>) Representative external photographs showing ocular surface morbidities in each treatment cohort from <xref ref-type="fig" rid="fig8">Figure 8</xref> at the experiment endpoint. Note the sex-biased impact in the CVF-treated GVHD group where treatment limits eyelid swelling in female but not male mice. (<bold>B</bold>) Ophthalmic disease scores for each experimental group by sex (<italic>n</italic> = 5 females or three males per group; two-way ANOVA, Bonferroni).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48378-fig8-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Mechanistic advances in our understanding of the complement cascade’s physiologic regulation and pathologic contributions in disease have predictably spawned substantial investments in complement-targeted drug development over the past decade (<xref ref-type="bibr" rid="bib41">Harris et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Ricklin et al., 2018</xref>; <xref ref-type="bibr" rid="bib117">Tomlinson and Thurman, 2018</xref>). The ocular surface is a unique milieu in which pharmacologic modulation of the complement pathway may limit the severity of inflammatory disease and improve clinical outcomes. This study provides proof of concept that such interventions may have important clinical impacts on ocular surface disease, and specifically neuropathic sensory disorders affecting the cornea. Complement-targeted drug development for ophthalmic use has almost exclusively focused on AMD with some interest in neuromyelitis optica (NMO), Stargardt disease, and autoimmune uveitis (<xref ref-type="bibr" rid="bib41">Harris et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Pittock et al., 2013</xref>). By July 2019, there were no complement-specific therapeutics indicated for ocular surface use registered on <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (search strings: ‘complement’ / ‘C3’ / ‘C5’ / ‘eculizumab’ AND ‘cornea’, ‘conjunctiva’, ‘dry eye’, ‘keratitis’, OR ‘ocular surface’). Nonetheless, the complement pathway is implicated in the pathophysiology of several ocular surface diseases (<xref ref-type="bibr" rid="bib6">Bora et al., 2008</xref>). The current investigation provides an important advancement in this arena by demonstrating that dysregulated complement activation can specifically contribute to sensory nerve damage in the cornea.</p><p>While corneal nerves are increasingly implicated in maintenance of corneal immune privilege (<xref ref-type="bibr" rid="bib81">Paunicka et al., 2015</xref>; <xref ref-type="bibr" rid="bib77">Neelam et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">Guzmán et al., 2018</xref>), this study is the first to identify that C3 is involved in the pathobiology of corneal sensory nerve damage. However, the individual fates of damaged corneal nerves were not explored herein. Lessons from peripheral nerve injury in other settings indicate that some damaged nerves undergo apoptosis, yet effectively promoting functional regeneration of surviving neurons remains a major clinical hurtle (<xref ref-type="bibr" rid="bib25">Doron-Mandel et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Menorca et al., 2013</xref>; <xref ref-type="bibr" rid="bib101">Scheib and Höke, 2013</xref>; <xref ref-type="bibr" rid="bib105">Shacham-Silverberg et al., 2018</xref>). Likewise, promoting functional regeneration of damaged corneal nerves is important for restoration of immune privilege and ocular surface health. Our approach evaluated sensory nerve damage in murine models of T cell-dependent ocular surface disease including HSV-1 keratitis, OVA-induced AED, and ocular GHVD. The lack of a sensory phenotype in the AED model was unanticipated in light of evidence that patients with severe allergy exhibit changes in corneal nerve morphology (<xref ref-type="bibr" rid="bib46">Hu et al., 2008</xref>; <xref ref-type="bibr" rid="bib54">Le et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Leonardi et al., 2012</xref>). This contrasting model underscores the context-dependency of sensation loss during corneal inflammation.</p><p>While we focused on C3 in HSV-1 keratitis and ocular GVHD due to the direct link to overt corneal sensation loss, complement may still have an important role in mediating neurogenic hypersensitivities in AED. In addition to loss of mechano-sensory function, corneal nerve pathologies can involve a broad array of neuropathic clinical symptoms including dryness, itch, and pain (<xref ref-type="bibr" rid="bib3">Andersen et al., 2017</xref>). Inflammatory mediators facilitate neuropathic hypersensitivities, but the therapeutic potential of complement inhibition is often overlooked (<xref ref-type="bibr" rid="bib4">Baral et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Fritzinger and Benjamin, 2016</xref>). Moreover, the cornea produces many neurotrophic factors that influence sensory innervation in health and disease (<xref ref-type="bibr" rid="bib100">Sacchetti and Lambiase, 2017</xref>; <xref ref-type="bibr" rid="bib127">Yu et al., 2015</xref>). Given the involvement of C3 activation in sensory nerve damage, future investigation into crosstalk between complement and other neurotropic factors in the cornea is warranted. Furthermore, AED is driven primarily by a combined Th2/Th17 CD4 T cell response that differs from the Th1 bias observed in HSV-1 keratitis and ocular GVHD (<xref ref-type="bibr" rid="bib44">Herretes et al., 2015</xref>; <xref ref-type="bibr" rid="bib98">Saban et al., 2013</xref>; <xref ref-type="bibr" rid="bib112">Tang and Hendricks, 1996</xref>). This suggests that Th1 cytokines such as IFNγ, IL-2, and lymphotoxin-alpha may be important in coordinating corneal sensation loss. Nonetheless, the unique inflammatory milieus and differential polarizations of cornea-infiltrating T cells across these disease models may also influence the downstream effects of complement activation in the tissue microenvironment (<xref ref-type="bibr" rid="bib117">Tomlinson and Thurman, 2018</xref>). Future studies are needed to broaden the scope of these observations to other peripheral nerve diseases. For example, complement-mediated microvascular damage in diabetes correlates with neuropathy (<xref ref-type="bibr" rid="bib86">Rasmussen et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Rosoklija et al., 2000</xref>). While diabetic peripheral neuropathy can lead to neurotropic corneal ulcerations (<xref ref-type="bibr" rid="bib33">Gao et al., 2016b</xref>), the role of complement in diabetic corneal disease is currently unknown.</p><p>Complement enhances clearance of infected cells and nascent virions during HSV-1 infection (<xref ref-type="bibr" rid="bib50">Kostavasili et al., 1997</xref>; <xref ref-type="bibr" rid="bib64">Lubinski et al., 2002</xref>; <xref ref-type="bibr" rid="bib70">McNearney et al., 1987</xref>). Importantly, HSV-1 can also evade C3 activation through endogenous expression of glycoprotein C (gC). By limiting C3b deposition on infected cells and nascent virions, gC can inhibit subsequent C5 binding and membrane attack complex (MAC) formation (<xref ref-type="bibr" rid="bib50">Kostavasili et al., 1997</xref>; <xref ref-type="bibr" rid="bib64">Lubinski et al., 2002</xref>; <xref ref-type="bibr" rid="bib70">McNearney et al., 1987</xref>; <xref ref-type="bibr" rid="bib114">Tegla et al., 2011</xref>). This could explain why herpetic keratitis is less severe in rabbits infected with a gC-deficient strain of HSV-1 during acute infection (<xref ref-type="bibr" rid="bib27">Drolet et al., 2004</xref>). However, this gC-mediated viral evasion strategy may also be cell type-dependent. Cell culture modeling indicates that neuronal cells maintain host-encoded complement regulator expression more efficiently and are more resistant to MAC deposition than epithelial cells upon HSV-1 infection (<xref ref-type="bibr" rid="bib87">Rautemaa et al., 2002</xref>). Accordingly, complement-mediated sensory nerve damage in HSV-1 keratitis may reflect a maladaptive outcome of host-defense. This is consistent with our data showing that immunologically naive C3<sup>-/-</sup> mice maintain corneal sensation and innervation, yet they exhibit concomitant enhancement of viral shedding in the tear film and increased viral burden in the TG by day 7 p.i. The absence of a concordant difference in HSV-1 titers in corneas from WT and C3<sup>-/-</sup> mice is likely explained by the potent antiviral effects of type-1 interferon (<xref ref-type="bibr" rid="bib17">Conrady et al., 2011</xref>; <xref ref-type="bibr" rid="bib96">Royer and Carr, 2016</xref>). This suggests that the maintenance of corneal innervation in C3<sup>-/-</sup> mice enables enhanced shedding of nascent virions produced within the TG. Moreover, there is no difference in the amount of latent HSV-1 in the TG of naive WT and C3<sup>-/-</sup> mice 30 days after ocular HSV-1 challenge (<xref ref-type="bibr" rid="bib95">Royer et al., 2019</xref>). Taken together, this evidence indicates that although C3 is involved in progression of keratitis and sensory nerve fiber retraction during acute infection, it likely does not contribute to complete elimination of infected nerves.</p><p>The studies reported herein involve immunologically naive mice, but the impacts of preexisting humoral immune responses on complement pathway activation and regulation in the cornea during HSV-1 infection remain incompletely understood. This point is of considerable importance clinically, as herpes-associated neurotropic keratitis typically develops as a result of recurrent corneal infections in patients (<xref ref-type="bibr" rid="bib38">Hamrah et al., 2010</xref>). Furthermore, we have recently reported that C3 is essential for optimal antibody-dependent viral clearance following ocular HSV-1 challenge in mice (<xref ref-type="bibr" rid="bib95">Royer et al., 2019</xref>; <xref ref-type="bibr" rid="bib93">Royer et al., 2017</xref>). While vaccinated animals did not exhibit corneal sensation loss following ocular HSV-1 infection in those studies, deposition of the terminal C3 cleavage product C3d was present in the corneal epithelium (<xref ref-type="bibr" rid="bib93">Royer et al., 2017</xref>). Host gene expression data herein corroborates that HSV-1 infection creates an imbalance in the local complement effector to regulator expression ratios that contribute to aberrant complement pathway activation in the cornea. This imbalance in ‘complement proteostasis’ may favor deposition of complement fragments and sublytic MAC on corneal sensory nerve fibers (<xref ref-type="bibr" rid="bib114">Tegla et al., 2011</xref>; <xref ref-type="bibr" rid="bib118">Triantafilou et al., 2013</xref>). Notwithstanding, the nerve-intrinsic molecular mechanisms responsible for trigeminal sensory fiber retraction, neuronal death, or axonal regeneration in the cornea are largely unknown (<xref ref-type="bibr" rid="bib108">Stepp et al., 2017</xref>). Future work is needed to identify the respective complement activation pathways involved in pathologic and protective immune responses to HSV-1 in the cornea.</p><p>Identification of the complement pathway’s role in initiating corneal sensation loss following HSV-1 infection is an important advancement in the mechanistic understanding of this disease process, as it introduces an array of potential drug targets for local therapy. Previous observations note that complement activation in antigen-induced keratitis may be mediated by cellular immune mechanisms (<xref ref-type="bibr" rid="bib119">Verhagen et al., 1992</xref>). The identification of CSF1R<sup>+</sup> macrophages/monocytes as a local source of C3 during infection (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) is also critical, as these cells are recruited to the cornea in the early stages of HSV-1 infection and are associated with corneal nerve damage in HSV-1 keratitis (<xref ref-type="bibr" rid="bib12">Chucair-Elliott et al., 2017b</xref>; <xref ref-type="bibr" rid="bib18">Conrady et al., 2013</xref>). Moreover, CD4 T cells coordinate this pathology. Our data corroborate findings from the Hendricks’ lab showing that CD4 T cells are associated with corneal sensation loss in HSV-1 keratitis (<xref ref-type="bibr" rid="bib128">Yun et al., 2014</xref>), yet our adoptive transfer experiments establish that this process is not dependent upon endogenous C3 production by cornea-infiltrating donor T cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Notably, the tempo of HSV-associated sensation loss was consistent among models once initiated (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig3">Figure 3A</xref>). However, the initial onset was delayed by one day in the adoptive transfer model. This likely reflects the relative lymphopenic status of T cell-reconstituted TCRα<sup>-/-</sup> mice compared to WT mice (compare <xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><p>Corneal sensation loss in HSV-1 infection and ocular GVHD shared a common mechanism dependent upon CD4<sup>+</sup> T cells and complement C3. The role of intracellular C3 in regulating human Th1 responses has received much attention in recent years (<xref ref-type="bibr" rid="bib29">Elvington et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Hansen et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Liszewski et al., 2013</xref>). Such studies involve CD3 and CD46 stimulation to activate human CD4 T cells in vitro. However, mice do not express CD46. Instead, anaphylatoxin receptor signaling has been shown to modulate Th1 cytokine production in murine T cells (<xref ref-type="bibr" rid="bib109">Strainic et al., 2008</xref>). Our ex vivo re-stimulation data clearly show that there is no defect in IFNγ production by CD4 T cells from C3<sup>-/-</sup> mice following HSV-1 infection. Others have shown similar data based on T cell proliferation in response to re-stimulation with HSV-1 antigen (<xref ref-type="bibr" rid="bib21">Da Costa et al., 1999</xref>). In contrast, a reduction in IFNγ production by CD4 T cells from C3<sup>-/-</sup> mice was reported following in vitro expansion under Th1 polarizing conditions (<xref ref-type="bibr" rid="bib59">Liszewski et al., 2013</xref>). Nonetheless, it is possible that anaphylatoxin receptor signaling from locally produced C3a (and potentially C5a generated downstream) modulates T cell effector function upon extravasation into the inflamed cornea. The precise relationships between T cells and C3 in our mouse models of corneal neuropathic disease remain to be identified. Our working hypothesis involves an indirect mechanism whereby sublytic MAC deposition from local complement activation damages sensory nerves, which are then cleared by T cell-activated phagocytes or other cytolytic cells. These could include tissue-resident and infiltrating leukocytes (macrophages, monocytes, dendritic cells, and NK cells) as well as nerve-associated corneal epithelial cells (<xref ref-type="bibr" rid="bib7">Buela and Hendricks, 2015</xref>; <xref ref-type="bibr" rid="bib12">Chucair-Elliott et al., 2017b</xref>; <xref ref-type="bibr" rid="bib32">Gao et al., 2016a</xref>; <xref ref-type="bibr" rid="bib52">Koyama and Hill, 2016</xref>; <xref ref-type="bibr" rid="bib61">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib94">Royer et al., 2018</xref>; <xref ref-type="bibr" rid="bib104">Seyed-Razavi et al., 2014</xref>; <xref ref-type="bibr" rid="bib108">Stepp et al., 2017</xref>). Emerging evidence indicates that the plasma membranes of corneal nerves and epithelial cells fuse thereby enabling cytosolic exchange (<xref ref-type="bibr" rid="bib108">Stepp et al., 2017</xref>). In light of this, it is plausible that complement-mediated damage to corneal epithelial cells has a direct impact on sensory nerves.</p><p>Although corneal nerve damage is an established pathology in animal models of HSV-1 infection (<xref ref-type="bibr" rid="bib9">Chucair-Elliott et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">He et al., 2017b</xref>; <xref ref-type="bibr" rid="bib128">Yun et al., 2014</xref>), this is the first report documenting loss of corneal mechano-sensory function in ocular GVHD. Notably, patients rarely exhibit neurological manifestations of GVHD affecting other tissues/organs (<xref ref-type="bibr" rid="bib35">Grauer et al., 2010</xref>). Corneal sensation loss may provide a clinical benchmark for initiation of targeted therapies to curb progression of ocular GVHD in patients. Data from our animal model of GVHD suggest that corneal sensation loss is an early warning sign of progressive ocular and systemic GVHD. Corneal sensation measurements are warranted in patients following HSCT to substantiate this finding among those who develop chronic GVHD. Published imaging studies confirm that corneal nerve remodeling occurs in patients with ocular GVHD (<xref ref-type="bibr" rid="bib42">He et al., 2017a</xref>; <xref ref-type="bibr" rid="bib116">Tepelus et al., 2017</xref>); therefore, clinical studies to delineate the kinetics of disease onset are needed. Complement C3 is a known driver of systemic GVHD (<xref ref-type="bibr" rid="bib53">Kwan et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="bib103">Seignez et al., 2017</xref>), and our data show that aberrant complement pathway activation also contributes to the pathogenesis of ocular GVHD including corneal sensation loss. Furthermore, localized CVF treatment preserved corneal sensation in both sexes during ocular GVHD, but treatment only abrogated other facets of ocular surface disease in female mice. This dimorphic outcome may reflect insufficient maintenance of C3 depletion in the ocular surface microenvironment, as animals were only treated twice weekly. Furthermore, complement activity is reportedly limited by terminal pathway components in female mice compared to males (<xref ref-type="bibr" rid="bib51">Kotimaa et al., 2016</xref>). Collectively, our data suggest that sensory nerve involvement may be a unique facet and treatment target in ocular GVHD.</p><p>While the complement pathway has many components, C3 is the heart of the pathway and its activation products mediate virtually all downstream pathway functions. Accordingly, we used CVF to target complement activation in models of HSV-1 keratitis and ocular GVHD as a proof of concept for local delivery of complement-targeted therapeutics for ocular surface disease. In contrast to the neurotoxic effects of complete cobra venom, purified CVF is a ‘nontoxic’ derivative. CVF forms a biochemically stable convertase to rapidly hydrolyze mammalian C3 and C5. This ultimately results in complement inactivation via effector consumption (<xref ref-type="bibr" rid="bib122">Vogel and Fritzinger, 2010</xref>). The only recorded side effect of purified CVF administration in rodents is transitory anaphylatoxin-mediated pulmonary inflammation resulting in acute respiratory distress (<xref ref-type="bibr" rid="bib84">Proctor et al., 2006</xref>; <xref ref-type="bibr" rid="bib122">Vogel and Fritzinger, 2010</xref>). In our hands, respiratory distress was observed in some mice following the initial sub-conjunctival CVF injection irrespective of group assignment (animals were euthanized). However, topical CVF administration did not provoke respiratory or corneal abnormalities in any animals. Previous findings also show that topical CVF administration has no obvious effects on corneal health or transparency (<xref ref-type="bibr" rid="bib129">Zaidi et al., 2010</xref>).</p><p>Experimental CVF administration was once thought to directly stimulate T cells, but such effects were later attributed to mitogen contamination (<xref ref-type="bibr" rid="bib97">Rumjanek et al., 1978</xref>; <xref ref-type="bibr" rid="bib8">Cauvi et al., 2012</xref>). Because our disease models were T cell-dependent, we utilized highly-purified CVF from a commercial source for our studies. Moreover, we found no evidence to suggest that CVF impacted T cell responses outside of the eye. Local CVF treatment reduced corneal T cell infiltration following HSV-1 infection (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). However, this is likely due to reduced inflammation overall in C3-depleted corneas (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Likewise, ocular CVF treatment in the GVHD model did not impact on the total numbers of T cells in the corneas at the experiment endpoint. However, we have not excluded the possibility that CVF treatment may delay the tempo of T cell influx. Nonetheless, CVF administration preserved corneal sensation in both disease models. By addressing the ‘heart’ of the complement pathway (C3), this study opens the door to future investigation to further elucidate the relevant pathomechanisms and corresponding therapeutic targets. The relevant complement activation pathways (classical, alternative, lectin, terminal), cellular targets, and impacts of anaphylatoxin receptor signaling are topics of future investigation.</p><p>Complement activation is a double-edged sword in the cornea, as activation can be either protective or harmful. Low-level complement turnover is observed in healthy corneas/tears, and complement may even contribute to the relative ‘paucibacterial’ state of the ocular surface microbiome (<xref ref-type="bibr" rid="bib23">Doan et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">McDermott, 2013</xref>; <xref ref-type="bibr" rid="bib125">Willcox et al., 1997</xref>). The mechanisms regulating each complement-mediated effect remain incompletely understood. Elucidation of how complement activation is triggered, the relevant molecular mechanisms of its downstream signaling, and contributions to pathology will promote an important advancement in drug development for ocular surface disease. Animal models are necessary for mechanistic studies when it comes to understanding complement pathway regulation, especially in dynamic tissue microenvironments; however, differences in complement regulation exist between mouse and man that will also have to be resolved to further assess the translational potential (<xref ref-type="bibr" rid="bib47">Jacobson and Weis, 2008</xref>). This certainly applies to putative complement-targeted therapeutics for ocular surface treatment. Even among individual patients, small nucleotide polymorphisms evoke changes in complement activity that have major impacts on disease risks. Such genetic linkages, dubbed ‘complotype,’ are important in differential susceptibility to AMD (<xref ref-type="bibr" rid="bib40">Harris et al., 2012</xref>; <xref ref-type="bibr" rid="bib80">Paun et al., 2016</xref>). Accordingly, complotype differences may help explain differential susceptibility patterns in a variety of ocular surface diseases. Our data herein have demonstrated successful prophylactic intervention in repressing complement-mediated sensory nerve pathology in two well characterized experimental T cell-dependent corneal disease models. Other avenues of future investigation are also needed to determine the efficacy of therapeutic intervention on established ocular surface diseases. Successful implementation of complement-targeted therapeutics for topical ophthalmic use may provide the benefit of controlling insidious ocular surface diseases without the risks associated with systemic therapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Strain, strain background (<italic>Mus musculus</italic>, C57BL/6J)</td><td>Wildtype C57BL/6 (WT)</td><td>Jackson Laboratories</td><td>Stock # 000664</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>, C57BL/6J)</td><td>Complement C3 deficient (C3-/-)</td><td>Jackson Laboratories</td><td>Stock # 029661</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>, C57BL/6J)</td><td>T cell receptor alpha deficient (TCRα-/-)</td><td>Jackson Laboratories</td><td>Stock # 002116</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>, C57BL/6J)</td><td>Transgenic OVA-specific CD4 T cells (OT-II)</td><td>Jackson Laboratories</td><td>Stock # 004194</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>, C57BL/6J)</td><td>Transgenic Csf1r-eGFP (MAFIA)</td><td>Jackson Laboratories</td><td>Stock # 005070</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>, C57BL/6J)</td><td>C3.SW-H2b</td><td>Jackson Laboratories</td><td>Stock # 000438</td><td/></tr><tr><td>Strain, strain background (Herpes simplex virus type 1, McKrae)</td><td>HSV-1</td><td><xref ref-type="bibr" rid="bib66">Macdonald et al., 2012</xref>; <xref ref-type="bibr" rid="bib123">Watson et al., 2012</xref></td><td>N/A</td><td>Originally from Brian Gebhardt</td></tr><tr><td>Cell line (<italic>Cercopithecus aethiops</italic>)</td><td>Vero</td><td>American Type Culture Collection (ATCC)</td><td>Cat. # CCL-81</td><td>see Materials and methods</td></tr><tr><td>Chemical compound, drug</td><td>Cobra Venom Factor, <italic>Naja naja kaouthia</italic></td><td>Millipore-Sigma</td><td>Cat. # 233552</td><td/></tr><tr><td>Commercial assay or kit</td><td>Anti-mouse CD90.2 IMag particles</td><td>BD</td><td>Cat. # 551518</td><td/></tr><tr><td>Commercial assay or kit</td><td>Anti-mouse CD4 microbeads</td><td>Miltenyi Biotec</td><td>Cat. # 130-049-201</td><td/></tr><tr><td>Commercial assay or kit</td><td>Anti-mouse CD8 microbeads</td><td>Miltenyi Biotec</td><td>Cat. # 130-116-478</td><td/></tr><tr><td>Commercial assay or kit</td><td>Anti-mouse CD90.2 microbeads</td><td>Miltenyi Biotec</td><td>Cat. # 130-049-101</td><td/></tr><tr><td>Commercial assay or kit</td><td>Anti-mouse CD45 microbeads</td><td>Miltenyi Biotec</td><td>Cat. # 130-052-301</td><td/></tr><tr><td>Commercial assay or kit</td><td>Anti-mouse EpCAM microbeads</td><td>Miltenyi Biotec</td><td>Cat. # 130-105-958</td><td/></tr><tr><td>Antibody</td><td>Rabbit polyclonal IgG (anti-mouse beta-III tubulin)</td><td>Abcam</td><td>Cat. # ab18207</td><td>(1:500)</td></tr><tr><td>Antibody</td><td>AlexaFluor647 donkey polyclonal IgG <break/>(anti-rabbit IgG)</td><td>Jackson Immunoresearch</td><td>Cat. # 711-605-152</td><td>(1:1000)</td></tr><tr><td>Antibody</td><td>Anti-mouse CD3e FITC <break/>(Clone: 145–2 C11)</td><td>eBioscience (ThermoFisher)</td><td>Cat. # 11-0031-82</td><td>(1:500)</td></tr><tr><td>Other</td><td>Roche Liberase TL</td><td>Sigma Aldrich</td><td>Cat. # 5401020001</td><td>see Materials and methods</td></tr><tr><td>Commercial assay or kit</td><td>C3 ELISA</td><td>Abcam</td><td>Cat. # ab157711</td><td/></tr><tr><td>Commercial assay or kit</td><td>Milliplex MAP Luminex Array</td><td>EMD Millipore</td><td>Custom Design</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>iScript cDNA synthesis kit</td><td>Biorad</td><td>Cat. # 1708891</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>Sso Advanced SYBR Green qPCR Supermix</td><td>Biorad</td><td>Cat. # 1725270</td><td/></tr><tr><td>Other</td><td>Trizol</td><td>ThermoFisher</td><td>Cat. # 15596026</td><td>see Materials and methods</td></tr><tr><td>Software, algorithm</td><td>Prism 6</td><td>GraphPad</td><td>N/A</td><td/></tr><tr><td>Software, algorithm</td><td>Imaris x64 (8.2.1)</td><td>Bitplane</td><td>N/A</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal models</title><p>Mouse strains were originally purchased from The Jackson Laboratory (Bar Harbor, ME). These include: C57BL/6, C3<sup>-/-</sup> (stock #029661), TCRα<sup>-/-</sup> (stock # 002116), OT-II (stock #004194), MAFIA/CSF1R-GFP (stock #005070), C3.SW-H2<sup>b</sup> (stock #000438), and B6-GFP (stock #003291). Colonies were maintained in select-pathogen-free vivaria at the University of Oklahoma Health Sciences Center or Duke University Medical Center. Research was performed in accordance with protocols approved by respective institutional animal care and use committees.</p><p>For all procedures relating to ocular HSV-1 infection, C57BL/6-background mice were anesthetized with ketamine and xylazine and euthanized by cardiac perfusion (<xref ref-type="bibr" rid="bib94">Royer et al., 2018</xref>). For infection, corneas were scratched to expose the epithelium and 1000 plaque forming units (PFU) of HSV-1 McKrae was applied to each eye. Viral stocks were propagated and infectious titers quantified by standard plaque assay on Vero cells (American Type Culture Collection, Manassas, VA) as previously reported (<xref ref-type="bibr" rid="bib91">Royer et al., 2015</xref>). For adoptive transfers, T cells were purified from splenocyte preparations using a BioRad S3e cell sorter (Hercules, CA). Corneal complement C3 depletion was achieved by subconjunctival injection of CVF (Cat. # 233552, Millipore Sigma, Burlington, MA) followed by topical maintenance dosing as described in respective figure legends.</p><p>Allergic eye disease was initiated in B6 mice as previously described (<xref ref-type="bibr" rid="bib1">Ahadome et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="bib102">Schlereth et al., 2012</xref>). Briefly, hypersensitivity was elicited via intraperitoneal immunization with 10 μg ovalbumin (OVA) adjuvanted with 1 mg Alum and 300 ng pertussis toxin (all from Sigma-Aldrich Corp., St. Louis, MO). Ocular allergy was subsequently induced via daily eyedrop challenge containing 250 μg OVA (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Clinical signs of AED were scored daily using established criteria (<xref ref-type="bibr" rid="bib102">Schlereth et al., 2012</xref>). Animals were euthanized by CO<sub>2</sub> asphyxiation for tissue collection.</p><p>Induction of GVHD was based on an established T-dependent, MHC-matched unrelated donor model (<xref ref-type="bibr" rid="bib82">Perez et al., 2016</xref>). Briefly, C3-SW.H2<sup>b</sup> mice were lethally irradiated (10.5 Gy, Cs-137) and reconstituted with 5 × 10<sup>6</sup> T cell-depleted bone marrow (TCD-BM) cells from allogeneic C57BL/6 (H2<sup>b</sup>) mice. T cell depletion was achieved using BD anti-mouse CD90.2 IMag particles (Cat. # 551518, San Jose, CA). Control groups received TCD-BM only, but GVHD onset required reconstitution with TCD-BM and T cells. T cells were isolated from B6 splenocytes using immunomagnetic microbeads (Miltenyi Biotec, San Diego, CA) targeting CD4 (Cat. #130-049-201), CD8 (Cat. #130-116-478), or CD90.2 (Cat. #130-049-101) according to the manufacturer’s instructions. Cell purity was evaluated by flow cytometry (~80%) and adjusted such that 1.3 × 10<sup>6</sup> CD4<sup>+</sup> or CD8<sup>+</sup> T cells or 2.3 × 10<sup>6</sup> CD3<sup>+</sup> T cells were injected into each recipient with TCD-BM. Irradiated animals received water containing gentamicin (6.6 μg/ml) for ten days following irradiation (Henry Schein Animal Health, Dublin,OH). Supplical nutritional paste (Henry Schein) was also provided ad libitum to reduce weight loss. Systemic manifestations of GVHD were scored using established criteria (<xref ref-type="bibr" rid="bib82">Perez et al., 2016</xref>) and ocular disease scored according to <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec><sec id="s4-2"><title>Corneal nerve mechano-sensation, imaging, and morphometric analysis</title><p>Corneal mechano-sensory function was measured on non-anesthetized mice with a Luneau Cochet-Bonnet esthesiometer (Western Ophthalmics, Lynwood, WA) in 0.5 cm increments on a scale of 0 to 6 cm as previously described (<xref ref-type="bibr" rid="bib9">Chucair-Elliott et al., 2015</xref>). Sensation scores reflect the longest filament length capable of eliciting replicate blink reflexes when applied to the central cornea. A Bioptigen spectral domain optical coherence tomography (SD-OCT) system (Leica Microsystems, Buffalo Grove, IL) was utilized to evaluate corneal inflammation and edema in vivo (<xref ref-type="bibr" rid="bib26">Downie et al., 2014</xref>). Digital photography of the external eye was captured with a Leica MZ16 FA stereomicroscope.</p><p>Corneal nerves were imaged in flat-mounted corneal buttons as described (<xref ref-type="bibr" rid="bib9">Chucair-Elliott et al., 2015</xref>). Briefly, corneas were harvested with the limbus intact, fixed, permeabilized, and labeled with Abcam anti-mouse beta-III tubulin primary antibody (Cat. # ab18207, Cambridge, MA) and a corresponding AlexaFluor647-conjugated secondary antibody (Cat. # 711-605-152, Jackson Immunoresearch, West Grove, PA). Corneas were also labeled with an eBioscience FITC-conjugated anti-mouse CD3ε antibody (ThermoFisher, Waltham, MA). Slides were imaged using an Olympus Fluoview1200 laser scanning confocal (Center Valley, PA) or a Nikon AR1 HD resonant scanning confocal (Melville, NY) microscope with sequential channel scanning.</p><p>Confocal z-stack images were evaluated using Imaris software (Bitplane, Concord, MA) to quantify corneal nerves densities and the total numbers of CD3<sup>+</sup> cells. Briefly, images were displayed as maximum intensity projections. Nerve volume per field of view was measured with the ‘create surface tool’ with manual thresholding for voxel area coverage of βIII tubulin<sup>+</sup> fibers (default parameters; smooth surface area detail set to 0.5 μm; background subtraction set to 8.0 μm). Total CD3<sup>+</sup> cells were quantified using the spots tool with default parameters, an estimated cell diameter of 8 μm, and classification using the quality filter method with manual thresholding. Morphometric nerve volume and cell count summary statistics were reported by the software per image (20x field of view). Nerve densities were normalized to the respective control group average.</p></sec><sec id="s4-3"><title>Flow cytometry and cell isolation</title><p>Secondary lymphoid organs were harvested and mechanically processed into single-cell suspensions (<xref ref-type="bibr" rid="bib91">Royer et al., 2015</xref>). Blood was collected from the facial vein and treated with erythrocyte lysis buffer prior to labeling. Corneas were digested in RPMI1640 media containing 0.26 Wünsch units of Roche LiberaseTL enzyme blend (Sigma Aldrich) at 37° C as described (<xref ref-type="bibr" rid="bib93">Royer et al., 2017</xref>). Cell suspensions were filtered and labeled with Fc block and fluorochrome-conjugated antibodies (eBioscience). In vitro T cell functional assays were performed as previously described (<xref ref-type="bibr" rid="bib91">Royer et al., 2015</xref>). Briefly, cells were stimulated using 50 ng PMA and 800 ng ionomycin for three hours and monensin added after one hour (BD Biosciences). Intracellular IFNγ expression was evaluated by flow cytometry using a BD cytofix/cytoperm staining kit. Samples were analyzed on a Miltenyi Biotec MacsQuant10 or a BD LSRFortessa flow cytometer with MacsQuantify or FacsDiva software, respectively. For downstream gene expression studies, cornea digests were fractionated with Miltenyi microbeads by sequentially targeting CD45 (Cat. # 130-052-301) and EpCAM (Cat. # 130-105-958) as described (<xref ref-type="bibr" rid="bib94">Royer et al., 2018</xref>). Alternatively, GFP-expressing cells were purified or depleted using a BioRad S3e cell sorter.</p></sec><sec id="s4-4"><title>Immunoassays and gene expression</title><p>Tissues were harvested and homogenized in phosphate-buffered saline (PBS) containing 1x Calbiochem protease inhibitor cocktail (Millipore Sigma). Serum was obtained by collecting blood from the facial vein into BD microtainer serum separator tubes. Tissue homogenates and serum were clarified by centrifugation at 10,000×<italic>g</italic>. Chemokine concentrations were determined using a BioRad Luminex system and Millipore Milliplex MAP technology. Concentrations of C3 were measured by ELISA (Abcam, Cat. # ab157711).</p><p>Gene expression studies were performed using RNA isolated from tissue and cells using the Trizol (ThermoFisher) method and converted to cDNA with iScript (BioRad). Real-time PCR was performed using PrimePCR technology with commercially validated primer sequences (Biorad) and a Biorad CFX-Connect thermocycler as directed. Relative expression was calculated using the 2<sup>–ΔΔCt</sup> method with GAPDH (glyceraldehyde 3-phosphate dehydrogenase) as a reference gene. Final PCR products were resolved on a 2% agarose gel and imaged with an Azure Biosystems C-series gel documentation system (Dublin, CA) to confirm <italic>C3</italic> expression in cell subsets.</p></sec><sec id="s4-5"><title>Statistical analysis</title><p>All data were evaluated using Prism six software (GraphPad, San Diego, CA). Statistical tests and post hoc analyses utilized are listed in each figure legend. Significance thresholds are indicated as follows *=<italic>P</italic> &lt; 0.05, **=<italic>P</italic> &lt; 0.01, ***=<italic>P</italic> &lt; 0.001 for all data.</p></sec><sec id="s4-6"><title>Supplementary materials</title><p>Supporting data are available online.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank Micaela Montgomery, Joan Kalnitsky, and Peter Saloupis for technical assistance. This project was supported by the following National Institutes of Health Grants: R01 EY021238 (DJJC), P30 EY021725 (University of Oklahoma Health Sciences Center), R01 EY021798 (DRS), P30 EY005722 (Duke University) and R01 EY024484 (VLP). Additional support was provided by unrestricted grants from Research to Prevent Blindness to the University of Oklahoma Health Sciences Center and Duke University. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Supervision, Funding acquisition, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Supervision, Funding acquisition, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Funding acquisition, Investigation, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Research was performed in accordance with protocols approved by institutional care and use committees at the University of Oklahoma Health Sciences Center (Protocol number 160-014-NSI) and Duke University (Protocol numbers A061-18-03 and A034-18-01).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.48378.021</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-48378-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data generated during this study are included in the manuscript.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahadome</surname> <given-names>SD</given-names></name><name><surname>Mathew</surname> <given-names>R</given-names></name><name><surname>Reyes</surname> <given-names>NJ</given-names></name><name><surname>Mettu</surname> <given-names>PS</given-names></name><name><surname>Cousins</surname> <given-names>SW</given-names></name><name><surname>Calder</surname> <given-names>VL</given-names></name><name><surname>Saban</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Classical dendritic cells mediate fibrosis directly via the retinoic acid pathway in severe eye allergy</article-title><source>JCI Insight</source><volume>1</volume><elocation-id>e87012</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.87012</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amouzegar</surname> <given-names>A</given-names></name><name><surname>Chauhan</surname> <given-names>SK</given-names></name><name><surname>Dana</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alloimmunity and tolerance in corneal transplantation</article-title><source>The Journal of Immunology</source><volume>196</volume><fpage>3983</fpage><lpage>3991</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600251</pub-id><pub-id pub-id-type="pmid">27183635</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>HH</given-names></name><name><surname>Yosipovitch</surname> <given-names>G</given-names></name><name><surname>Galor</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuropathic symptoms of the ocular surface: dryness, pain, and itch</article-title><source>Current Opinion in Allergy and Clinical Immunology</source><volume>17</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1097/ACI.0000000000000389</pub-id><pub-id pub-id-type="pmid">28858914</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baral</surname> <given-names>P</given-names></name><name><surname>Udit</surname> <given-names>S</given-names></name><name><surname>Chiu</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pain and immunity: implications for host defence</article-title><source>Nature Reviews Immunology</source><volume>19</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0147-2</pub-id><pub-id pub-id-type="pmid">30874629</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bora</surname> <given-names>NS</given-names></name><name><surname>Gobleman</surname> <given-names>CL</given-names></name><name><surname>Atkinson</surname> <given-names>JP</given-names></name><name><surname>Pepose</surname> <given-names>JS</given-names></name><name><surname>Kaplan</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Differential expression of the complement regulatory proteins in the human eye</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>34</volume><fpage>3579</fpage><lpage>3584</lpage><pub-id pub-id-type="pmid">7505007</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bora</surname> <given-names>NS</given-names></name><name><surname>Jha</surname> <given-names>P</given-names></name><name><surname>Bora</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The role of complement in ocular pathology</article-title><source>Seminars in Immunopathology</source><volume>30</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s00281-008-0110-y</pub-id><pub-id pub-id-type="pmid">18299835</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buela</surname> <given-names>KA</given-names></name><name><surname>Hendricks</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cornea-infiltrating and lymph node dendritic cells contribute to CD4<sup>+</sup> T cell expansion after herpes simplex virus-1 ocular infection</article-title><source>The Journal of Immunology</source><volume>194</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402326</pub-id><pub-id pub-id-type="pmid">25422507</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauvi</surname> <given-names>DM</given-names></name><name><surname>Toomey</surname> <given-names>CB</given-names></name><name><surname>Pollard</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease</article-title><source>Immunology</source><volume>135</volume><fpage>333</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2011.03545.x</pub-id><pub-id pub-id-type="pmid">22136142</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chucair-Elliott</surname> <given-names>AJ</given-names></name><name><surname>Zheng</surname> <given-names>M</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Degeneration and regeneration of corneal nerves in response to HSV-1 infection</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>56</volume><fpage>1097</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-15596</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chucair-Elliott</surname> <given-names>AJ</given-names></name><name><surname>Jinkins</surname> <given-names>J</given-names></name><name><surname>Carr</surname> <given-names>MM</given-names></name><name><surname>Carr</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>IL-6 contributes to corneal nerve degeneration after herpes simplex virus type I infection</article-title><source>The American Journal of Pathology</source><volume>186</volume><fpage>2665</fpage><lpage>2678</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2016.06.007</pub-id><pub-id pub-id-type="pmid">27497323</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chucair-Elliott</surname> <given-names>AJ</given-names></name><name><surname>Carr</surname> <given-names>MM</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Long-term consequences of topical dexamethasone treatment during acute corneal HSV-1 infection on the immune system</article-title><source>Journal of Leukocyte Biology</source><volume>101</volume><fpage>1253</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1189/jlb.4A1116-459R</pub-id><pub-id pub-id-type="pmid">28115476</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chucair-Elliott</surname> <given-names>AJ</given-names></name><name><surname>Gurung</surname> <given-names>HR</given-names></name><name><surname>Carr</surname> <given-names>MM</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Colony stimulating Factor-1 receptor expressing cells infiltrating the cornea control corneal nerve degeneration in response to HSV-1 infection</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>58</volume><fpage>4670</fpage><lpage>4682</lpage><pub-id pub-id-type="doi">10.1167/iovs.17-22159</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>SJ</given-names></name><name><surname>Bishop</surname> <given-names>PN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The eye as a complement dysregulation hotspot</article-title><source>Seminars in Immunopathology</source><volume>40</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s00281-017-0649-6</pub-id><pub-id pub-id-type="pmid">28948331</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname> <given-names>EV</given-names></name><name><surname>Tenner</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complement modulation of T cell immune responses during homeostasis and disease</article-title><source>Journal of Leukocyte Biology</source><volume>96</volume><fpage>745</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1189/jlb.3MR0214-109R</pub-id><pub-id pub-id-type="pmid">25210145</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colloca</surname> <given-names>L</given-names></name><name><surname>Ludman</surname> <given-names>T</given-names></name><name><surname>Bouhassira</surname> <given-names>D</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name><name><surname>Dickenson</surname> <given-names>AH</given-names></name><name><surname>Yarnitsky</surname> <given-names>D</given-names></name><name><surname>Freeman</surname> <given-names>R</given-names></name><name><surname>Truini</surname> <given-names>A</given-names></name><name><surname>Attal</surname> <given-names>N</given-names></name><name><surname>Finnerup</surname> <given-names>NB</given-names></name><name><surname>Eccleston</surname> <given-names>C</given-names></name><name><surname>Kalso</surname> <given-names>E</given-names></name><name><surname>Bennett</surname> <given-names>DL</given-names></name><name><surname>Dworkin</surname> <given-names>RH</given-names></name><name><surname>Raja</surname> <given-names>SN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuropathic pain</article-title><source>Nature Reviews Disease Primers</source><volume>3</volume><fpage>17002</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.2</pub-id><pub-id pub-id-type="pmid">28205574</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrady</surname> <given-names>CD</given-names></name><name><surname>Thapa</surname> <given-names>M</given-names></name><name><surname>Wuest</surname> <given-names>T</given-names></name><name><surname>Carr</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Loss of mandibular lymph node integrity is associated with an increase in sensitivity to HSV-1 infection in CD118-deficient mice</article-title><source>The Journal of Immunology</source><volume>182</volume><fpage>3678</fpage><lpage>3687</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803878</pub-id><pub-id pub-id-type="pmid">19265146</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrady</surname> <given-names>CD</given-names></name><name><surname>Jones</surname> <given-names>H</given-names></name><name><surname>Zheng</surname> <given-names>M</given-names></name><name><surname>Carr</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A functional type I interferon pathway drives resistance to cornea herpes simplex virus type 1 infection by recruitment of leukocytes</article-title><source>Journal of Biomedical Research</source><volume>25</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/S1674-8301(11)60014-6</pub-id><pub-id pub-id-type="pmid">21709805</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrady</surname> <given-names>CD</given-names></name><name><surname>Zheng</surname> <given-names>M</given-names></name><name><surname>Mandal</surname> <given-names>NA</given-names></name><name><surname>van Rooijen</surname> <given-names>N</given-names></name><name><surname>Carr</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IFN-α-driven CCL2 production recruits inflammatory monocytes to infection site in mice</article-title><source>Mucosal Immunology</source><volume>6</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.46</pub-id><pub-id pub-id-type="pmid">22692455</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname> <given-names>JP</given-names></name><name><surname>Nelson</surname> <given-names>JD</given-names></name><name><surname>Azar</surname> <given-names>DT</given-names></name><name><surname>Belmonte</surname> <given-names>C</given-names></name><name><surname>Bron</surname> <given-names>AJ</given-names></name><name><surname>Chauhan</surname> <given-names>SK</given-names></name><name><surname>de Paiva</surname> <given-names>CS</given-names></name><name><surname>Gomes</surname> <given-names>JAP</given-names></name><name><surname>Hammitt</surname> <given-names>KM</given-names></name><name><surname>Jones</surname> <given-names>L</given-names></name><name><surname>Nichols</surname> <given-names>JJ</given-names></name><name><surname>Nichols</surname> <given-names>KK</given-names></name><name><surname>Novack</surname> <given-names>GD</given-names></name><name><surname>Stapleton</surname> <given-names>FJ</given-names></name><name><surname>Willcox</surname> <given-names>MDP</given-names></name><name><surname>Wolffsohn</surname> <given-names>JS</given-names></name><name><surname>Sullivan</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TFOS DEWS II report executive summary</article-title><source>The Ocular Surface</source><volume>15</volume><fpage>802</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2017.08.003</pub-id><pub-id pub-id-type="pmid">28797892</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruzat</surname> <given-names>A</given-names></name><name><surname>Schrems</surname> <given-names>WA</given-names></name><name><surname>Schrems-Hoesl</surname> <given-names>LM</given-names></name><name><surname>Cavalcanti</surname> <given-names>BM</given-names></name><name><surname>Baniasadi</surname> <given-names>N</given-names></name><name><surname>Witkin</surname> <given-names>D</given-names></name><name><surname>Pavan-Langston</surname> <given-names>D</given-names></name><name><surname>Dana</surname> <given-names>R</given-names></name><name><surname>Hamrah</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Contralateral clinically unaffected eyes of patients with unilateral infectious keratitis demonstrate a sympathetic immune response</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>6612</fpage><lpage>6620</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-16560</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da Costa</surname> <given-names>XJ</given-names></name><name><surname>Brockman</surname> <given-names>MA</given-names></name><name><surname>Alicot</surname> <given-names>E</given-names></name><name><surname>Ma</surname> <given-names>M</given-names></name><name><surname>Fischer</surname> <given-names>MB</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Knipe</surname> <given-names>DM</given-names></name><name><surname>Carroll</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Humoral response to herpes simplex virus is complement-dependent</article-title><source>PNAS</source><volume>96</volume><fpage>12708</fpage><lpage>12712</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.22.12708</pub-id><pub-id pub-id-type="pmid">10535987</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jonge</surname> <given-names>RR</given-names></name><name><surname>van Schaik</surname> <given-names>IN</given-names></name><name><surname>Vreijling</surname> <given-names>JP</given-names></name><name><surname>Troost</surname> <given-names>D</given-names></name><name><surname>Baas</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Expression of complement components in the peripheral nervous system</article-title><source>Human Molecular Genetics</source><volume>13</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddh029</pub-id><pub-id pub-id-type="pmid">14662657</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doan</surname> <given-names>T</given-names></name><name><surname>Akileswaran</surname> <given-names>L</given-names></name><name><surname>Andersen</surname> <given-names>D</given-names></name><name><surname>Johnson</surname> <given-names>B</given-names></name><name><surname>Ko</surname> <given-names>N</given-names></name><name><surname>Shrestha</surname> <given-names>A</given-names></name><name><surname>Shestopalov</surname> <given-names>V</given-names></name><name><surname>Lee</surname> <given-names>CS</given-names></name><name><surname>Lee</surname> <given-names>AY</given-names></name><name><surname>Van Gelder</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Paucibacterial microbiome and resident DNA virome of the healthy conjunctiva</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>57</volume><fpage>5116</fpage><lpage>5126</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-19803</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobó</surname> <given-names>J</given-names></name><name><surname>Kocsis</surname> <given-names>A</given-names></name><name><surname>Gál</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Be on target: strategies of targeting alternative and lectin pathway components in Complement-Mediated diseases</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>1851</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01851</pub-id><pub-id pub-id-type="pmid">30135690</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doron-Mandel</surname> <given-names>E</given-names></name><name><surname>Fainzilber</surname> <given-names>M</given-names></name><name><surname>Terenzio</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Growth control mechanisms in neuronal regeneration</article-title><source>FEBS Letters</source><volume>589</volume><fpage>1669</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2015.04.046</pub-id><pub-id pub-id-type="pmid">25937120</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downie</surname> <given-names>LE</given-names></name><name><surname>Stainer</surname> <given-names>MJ</given-names></name><name><surname>Chinnery</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Monitoring of strain-dependent responsiveness to TLR activation in the mouse anterior segment using SD-OCT</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>55</volume><fpage>8189</fpage><lpage>8199</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-15595</pub-id><pub-id pub-id-type="pmid">25414189</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drolet</surname> <given-names>BS</given-names></name><name><surname>Mott</surname> <given-names>KR</given-names></name><name><surname>Lippa</surname> <given-names>AM</given-names></name><name><surname>Wechsler</surname> <given-names>SL</given-names></name><name><surname>Perng</surname> <given-names>GC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Glycoprotein C of herpes simplex virus type 1 is required to cause keratitis at low infectious doses in intact rabbit corneas</article-title><source>Current Eye Research</source><volume>29</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1080/02713680490504542</pub-id><pub-id pub-id-type="pmid">15512965</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einstein</surname> <given-names>LP</given-names></name><name><surname>Hansen</surname> <given-names>PJ</given-names></name><name><surname>Ballow</surname> <given-names>M</given-names></name><name><surname>Davis</surname> <given-names>AE</given-names></name><name><surname>Davis</surname> <given-names>JS</given-names></name><name><surname>Alper</surname> <given-names>CA</given-names></name><name><surname>Rosen</surname> <given-names>FS</given-names></name><name><surname>Colten</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans</article-title><source>Journal of Clinical Investigation</source><volume>60</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1172/JCI108876</pub-id><pub-id pub-id-type="pmid">332718</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elvington</surname> <given-names>M</given-names></name><name><surname>Liszewski</surname> <given-names>MK</given-names></name><name><surname>Bertram</surname> <given-names>P</given-names></name><name><surname>Kulkarni</surname> <given-names>HS</given-names></name><name><surname>Atkinson</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A C3(H20) recycling pathway is a component of the intracellular complement system</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>970</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1172/JCI89412</pub-id><pub-id pub-id-type="pmid">28192370</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooq</surname> <given-names>AV</given-names></name><name><surname>Shukla</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Herpes simplex epithelial and stromal keratitis: an epidemiologic update</article-title><source>Survey of Ophthalmology</source><volume>57</volume><fpage>448</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2012.01.005</pub-id><pub-id pub-id-type="pmid">22542912</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritzinger</surname> <given-names>DC</given-names></name><name><surname>Benjamin</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The complement system in neuropathic and postoperative pain</article-title><source>The Open Pain Journal</source><volume>9</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2174/1876386301609010026</pub-id><pub-id pub-id-type="pmid">28154610</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>P</given-names></name><name><surname>Yu</surname> <given-names>FS</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Intraepithelial dendritic cells and sensory nerves are structurally associated and functional interdependent in the cornea</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>36414</elocation-id><pub-id pub-id-type="doi">10.1038/srep36414</pub-id><pub-id pub-id-type="pmid">27805041</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>N</given-names></name><name><surname>Yan</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>P</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>FS</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Dendritic cell dysfunction and diabetic sensory neuropathy in the cornea</article-title><source>Journal of Clinical Investigation</source><volume>126</volume><fpage>1998</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1172/JCI85097</pub-id><pub-id pub-id-type="pmid">27064280</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gour</surname> <given-names>N</given-names></name><name><surname>Smole</surname> <given-names>U</given-names></name><name><surname>Yong</surname> <given-names>HM</given-names></name><name><surname>Lewkowich</surname> <given-names>IP</given-names></name><name><surname>Yao</surname> <given-names>N</given-names></name><name><surname>Singh</surname> <given-names>A</given-names></name><name><surname>Gabrielson</surname> <given-names>E</given-names></name><name><surname>Wills-Karp</surname> <given-names>M</given-names></name><name><surname>Lajoie</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>C3a is required for ILC2 function in allergic airway inflammation</article-title><source>Mucosal Immunology</source><volume>11</volume><fpage>1653</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0064-x</pub-id><pub-id pub-id-type="pmid">30104625</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grauer</surname> <given-names>O</given-names></name><name><surname>Wolff</surname> <given-names>D</given-names></name><name><surname>Bertz</surname> <given-names>H</given-names></name><name><surname>Greinix</surname> <given-names>H</given-names></name><name><surname>Kühl</surname> <given-names>JS</given-names></name><name><surname>Lawitschka</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Pavletic</surname> <given-names>SZ</given-names></name><name><surname>Holler</surname> <given-names>E</given-names></name><name><surname>Kleiter</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the consensus conference on clinical practice in chronic graft-versus-host disease</article-title><source>Brain</source><volume>133</volume><fpage>2852</fpage><lpage>2865</lpage><pub-id pub-id-type="doi">10.1093/brain/awq245</pub-id><pub-id pub-id-type="pmid">20846944</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzmán</surname> <given-names>M</given-names></name><name><surname>Miglio</surname> <given-names>MS</given-names></name><name><surname>Zgajnar</surname> <given-names>NR</given-names></name><name><surname>Colado</surname> <given-names>A</given-names></name><name><surname>Almejún</surname> <given-names>MB</given-names></name><name><surname>Keitelman</surname> <given-names>IA</given-names></name><name><surname>Sabbione</surname> <given-names>F</given-names></name><name><surname>Fuentes</surname> <given-names>F</given-names></name><name><surname>Trevani</surname> <given-names>AS</given-names></name><name><surname>Giordano</surname> <given-names>MN</given-names></name><name><surname>Galletti</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The mucosal surfaces of both eyes are immunologically linked by a neurogenic inflammatory reflex involving TRPV1 and substance P</article-title><source>Mucosal Immunology</source><volume>11</volume><fpage>1441</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0040-5</pub-id><pub-id pub-id-type="pmid">29867077</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajishengallis</surname> <given-names>G</given-names></name><name><surname>Reis</surname> <given-names>ES</given-names></name><name><surname>Mastellos</surname> <given-names>DC</given-names></name><name><surname>Ricklin</surname> <given-names>D</given-names></name><name><surname>Lambris</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Novel mechanisms and functions of complement</article-title><source>Nature Immunology</source><volume>18</volume><fpage>1288</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1038/ni.3858</pub-id><pub-id pub-id-type="pmid">29144501</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamrah</surname> <given-names>P</given-names></name><name><surname>Cruzat</surname> <given-names>A</given-names></name><name><surname>Dastjerdi</surname> <given-names>MH</given-names></name><name><surname>Zheng</surname> <given-names>L</given-names></name><name><surname>Shahatit</surname> <given-names>BM</given-names></name><name><surname>Bayhan</surname> <given-names>HA</given-names></name><name><surname>Dana</surname> <given-names>R</given-names></name><name><surname>Pavan-Langston</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study</article-title><source>Ophthalmology</source><volume>117</volume><fpage>1930</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2010.07.010</pub-id><pub-id pub-id-type="pmid">20810171</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname> <given-names>CB</given-names></name><name><surname>Willer</surname> <given-names>A</given-names></name><name><surname>Bayarri-Olmos</surname> <given-names>R</given-names></name><name><surname>Kemper</surname> <given-names>C</given-names></name><name><surname>Garred</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Expression of complement C3, C5, C3aR and C5aR1 genes in resting and activated CD4<sup>+</sup> T cells</article-title><source>Immunobiology</source><volume>224</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2018.12.004</pub-id><pub-id pub-id-type="pmid">30612786</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname> <given-names>CL</given-names></name><name><surname>Heurich</surname> <given-names>M</given-names></name><name><surname>Rodriguez de Cordoba</surname> <given-names>S</given-names></name><name><surname>Morgan</surname> <given-names>BP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The complotype: dictating risk for inflammation and infection</article-title><source>Trends in Immunology</source><volume>33</volume><fpage>513</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.it.2012.06.001</pub-id><pub-id pub-id-type="pmid">22749446</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname> <given-names>CL</given-names></name><name><surname>Pouw</surname> <given-names>RB</given-names></name><name><surname>Kavanagh</surname> <given-names>D</given-names></name><name><surname>Sun</surname> <given-names>R</given-names></name><name><surname>Ricklin</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Developments in anti-complement therapy; from disease to clinical trial</article-title><source>Molecular Immunology</source><volume>102</volume><fpage>89</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2018.06.008</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Ogawa</surname> <given-names>Y</given-names></name><name><surname>Mukai</surname> <given-names>S</given-names></name><name><surname>Saijo-Ban</surname> <given-names>Y</given-names></name><name><surname>Kamoi</surname> <given-names>M</given-names></name><name><surname>Uchino</surname> <given-names>M</given-names></name><name><surname>Yamane</surname> <given-names>M</given-names></name><name><surname>Ozawa</surname> <given-names>N</given-names></name><name><surname>Fukui</surname> <given-names>M</given-names></name><name><surname>Mori</surname> <given-names>T</given-names></name><name><surname>Okamoto</surname> <given-names>S</given-names></name><name><surname>Tsubota</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>In vivo confocal microscopy evaluation of ocular surface with Graft-Versus-Host Disease-Related dry eye disease</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>10720</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-10237-w</pub-id><pub-id pub-id-type="pmid">28878217</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Cosby</surname> <given-names>R</given-names></name><name><surname>Hill</surname> <given-names>JM</given-names></name><name><surname>Bazan</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Changes in corneal innervation after HSV-1 latency established with different reactivation phenotypes</article-title><source>Current Eye Research</source><volume>42</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.3109/02713683.2016.1167919</pub-id><pub-id pub-id-type="pmid">27315102</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herretes</surname> <given-names>S</given-names></name><name><surname>Ross</surname> <given-names>DB</given-names></name><name><surname>Duffort</surname> <given-names>S</given-names></name><name><surname>Barreras</surname> <given-names>H</given-names></name><name><surname>Yaohong</surname> <given-names>T</given-names></name><name><surname>Saeed</surname> <given-names>AM</given-names></name><name><surname>Murillo</surname> <given-names>JC</given-names></name><name><surname>Komanduri</surname> <given-names>KV</given-names></name><name><surname>Levy</surname> <given-names>RB</given-names></name><name><surname>Perez</surname> <given-names>VL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Recruitment of donor T cells to the eyes during ocular GVHD in recipients of MHC-Matched allogeneic hematopoietic stem cell transplants</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>2348</fpage><lpage>2357</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-15630</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname> <given-names>S</given-names></name><name><surname>Beja-Glasser</surname> <given-names>VF</given-names></name><name><surname>Nfonoyim</surname> <given-names>BM</given-names></name><name><surname>Frouin</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Ramakrishnan</surname> <given-names>S</given-names></name><name><surname>Merry</surname> <given-names>KM</given-names></name><name><surname>Shi</surname> <given-names>Q</given-names></name><name><surname>Rosenthal</surname> <given-names>A</given-names></name><name><surname>Barres</surname> <given-names>BA</given-names></name><name><surname>Lemere</surname> <given-names>CA</given-names></name><name><surname>Selkoe</surname> <given-names>DJ</given-names></name><name><surname>Stevens</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complement and microglia mediate early synapse loss in alzheimer mouse models</article-title><source>Science</source><volume>352</volume><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1126/science.aad8373</pub-id><pub-id pub-id-type="pmid">27033548</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Matsumoto</surname> <given-names>Y</given-names></name><name><surname>Adan</surname> <given-names>ES</given-names></name><name><surname>Dogru</surname> <given-names>M</given-names></name><name><surname>Fukagawa</surname> <given-names>K</given-names></name><name><surname>Tsubota</surname> <given-names>K</given-names></name><name><surname>Fujishima</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Corneal in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis</article-title><source>Ophthalmology</source><volume>115</volume><fpage>2004</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2008.05.010</pub-id><pub-id pub-id-type="pmid">18584874</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>AC</given-names></name><name><surname>Weis</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Comparative functional evolution of human and mouse CR1 and CR2</article-title><source>The Journal of Immunology</source><volume>181</volume><fpage>2953</fpage><lpage>2959</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.5.2953</pub-id><pub-id pub-id-type="pmid">18713965</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname> <given-names>JH</given-names></name><name><surname>Clark</surname> <given-names>JD</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Yorek</surname> <given-names>MS</given-names></name><name><surname>Usachev</surname> <given-names>YM</given-names></name><name><surname>Brennan</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nociceptive sensitization by complement C5a and C3a in mouse</article-title><source>Pain</source><volume>148</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2009.11.021</pub-id><pub-id pub-id-type="pmid">20031321</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knickelbein</surname> <given-names>JE</given-names></name><name><surname>Chan</surname> <given-names>CC</given-names></name><name><surname>Sen</surname> <given-names>HN</given-names></name><name><surname>Ferris</surname> <given-names>FL</given-names></name><name><surname>Nussenblatt</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inflammatory mechanisms of Age-related macular degeneration</article-title><source>International Ophthalmology Clinics</source><volume>55</volume><fpage>63</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1097/IIO.0000000000000073</pub-id><pub-id pub-id-type="pmid">26035762</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostavasili</surname> <given-names>I</given-names></name><name><surname>Sahu</surname> <given-names>A</given-names></name><name><surname>Friedman</surname> <given-names>HM</given-names></name><name><surname>Eisenberg</surname> <given-names>RJ</given-names></name><name><surname>Cohen</surname> <given-names>GH</given-names></name><name><surname>Lambris</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Mechanism of complement inactivation by glycoprotein C of herpes simplex virus</article-title><source>Journal of Immunology</source><volume>158</volume><fpage>1763</fpage><lpage>1771</lpage></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotimaa</surname> <given-names>J</given-names></name><name><surname>Klar-Mohammad</surname> <given-names>N</given-names></name><name><surname>Gueler</surname> <given-names>F</given-names></name><name><surname>Schilders</surname> <given-names>G</given-names></name><name><surname>Jansen</surname> <given-names>A</given-names></name><name><surname>Rutjes</surname> <given-names>H</given-names></name><name><surname>Daha</surname> <given-names>MR</given-names></name><name><surname>van Kooten</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex matters: systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components</article-title><source>Molecular Immunology</source><volume>76</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2016.06.004</pub-id><pub-id pub-id-type="pmid">27337595</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname> <given-names>M</given-names></name><name><surname>Hill</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alloantigen presentation and graft-versus-host disease: fuel for the fire</article-title><source>Blood</source><volume>127</volume><fpage>2963</fpage><lpage>2970</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-02-697250</pub-id><pub-id pub-id-type="pmid">27030390</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname> <given-names>WH</given-names></name><name><surname>Hashimoto</surname> <given-names>D</given-names></name><name><surname>Paz-Artal</surname> <given-names>E</given-names></name><name><surname>Ostrow</surname> <given-names>K</given-names></name><name><surname>Greter</surname> <given-names>M</given-names></name><name><surname>Raedler</surname> <given-names>H</given-names></name><name><surname>Medof</surname> <given-names>ME</given-names></name><name><surname>Merad</surname> <given-names>M</given-names></name><name><surname>Heeger</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antigen-presenting cell-derived complement modulates graft-versus-host disease</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>2234</fpage><lpage>2238</lpage><pub-id pub-id-type="doi">10.1172/JCI61019</pub-id><pub-id pub-id-type="pmid">22585573</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname> <given-names>Q</given-names></name><name><surname>Hong</surname> <given-names>J</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Sun</surname> <given-names>XH</given-names></name><name><surname>Xu</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>[Morphological characteristics of cornea in patients with vernal keratoconjunctivitis by in vivo laser scanning confocal microscopy]</article-title><source>Zhonghua Yan Ke Za Zhi Chin J Ophthalmol</source><volume>47</volume><fpage>416</fpage><lpage>422</lpage></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>H-S</given-names></name><name><surname>Hos</surname> <given-names>D</given-names></name><name><surname>Blanco</surname> <given-names>T</given-names></name><name><surname>Bock</surname> <given-names>F</given-names></name><name><surname>Reyes</surname> <given-names>NJ</given-names></name><name><surname>Mathew</surname> <given-names>R</given-names></name><name><surname>Cursiefen</surname> <given-names>C</given-names></name><name><surname>Dana</surname> <given-names>R</given-names></name><name><surname>Saban</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>3140</fpage><lpage>3148</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-16186</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JD</given-names></name><name><surname>Levin</surname> <given-names>SC</given-names></name><name><surname>Willis</surname> <given-names>EF</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Woodruff</surname> <given-names>TM</given-names></name><name><surname>Noakes</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complement components are upregulated and correlate with disease progression in the TDP-43<sup>Q331K</sup> mouse model of amyotrophic lateral sclerosis</article-title><source>Journal of Neuroinflammation</source><volume>15</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-018-1217-2</pub-id><pub-id pub-id-type="pmid">29859100</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname> <given-names>A</given-names></name><name><surname>Lazzarini</surname> <given-names>D</given-names></name><name><surname>Bortolotti</surname> <given-names>M</given-names></name><name><surname>Piliego</surname> <given-names>F</given-names></name><name><surname>Midena</surname> <given-names>E</given-names></name><name><surname>Fregona</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Corneal confocal microscopy in patients with vernal keratoconjunctivitis</article-title><source>Ophthalmology</source><volume>119</volume><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.09.018</pub-id><pub-id pub-id-type="pmid">22176802</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname> <given-names>J</given-names></name><name><surname>Pflugfelder</surname> <given-names>SC</given-names></name><name><surname>Yen</surname> <given-names>M</given-names></name><name><surname>Crouse</surname> <given-names>CA</given-names></name><name><surname>Atherton</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Detection of the complement (CD21)/Epstein-Barr virus receptor in human lacrimal gland and ocular surface epithelia</article-title><source>Regional Immunology</source><volume>3</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">1966579</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liszewski</surname> <given-names>MK</given-names></name><name><surname>Kolev</surname> <given-names>M</given-names></name><name><surname>Le Friec</surname> <given-names>G</given-names></name><name><surname>Leung</surname> <given-names>M</given-names></name><name><surname>Bertram</surname> <given-names>PG</given-names></name><name><surname>Fara</surname> <given-names>AF</given-names></name><name><surname>Subias</surname> <given-names>M</given-names></name><name><surname>Pickering</surname> <given-names>MC</given-names></name><name><surname>Drouet</surname> <given-names>C</given-names></name><name><surname>Meri</surname> <given-names>S</given-names></name><name><surname>Arstila</surname> <given-names>TP</given-names></name><name><surname>Pekkarinen</surname> <given-names>PT</given-names></name><name><surname>Ma</surname> <given-names>M</given-names></name><name><surname>Cope</surname> <given-names>A</given-names></name><name><surname>Reinheckel</surname> <given-names>T</given-names></name><name><surname>Rodriguez de Cordoba</surname> <given-names>S</given-names></name><name><surname>Afzali</surname> <given-names>B</given-names></name><name><surname>Atkinson</surname> <given-names>JP</given-names></name><name><surname>Kemper</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation</article-title><source>Immunity</source><volume>39</volume><fpage>1143</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.10.018</pub-id><pub-id pub-id-type="pmid">24315997</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Smith</surname> <given-names>CW</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Burns</surname> <given-names>AR</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NK cells modulate the inflammatory response to corneal epithelial abrasion and thereby support wound healing</article-title><source>The American Journal of Pathology</source><volume>181</volume><fpage>452</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.04.010</pub-id><pub-id pub-id-type="pmid">22728064</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Xue</surname> <given-names>Y</given-names></name><name><surname>Dong</surname> <given-names>D</given-names></name><name><surname>Xiao</surname> <given-names>C</given-names></name><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Song</surname> <given-names>F</given-names></name><name><surname>Fu</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Cai</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CCR2<sup>-</sup> and CCR2<sup>+</sup> corneal macrophages exhibit distinct characteristics and balance inflammatory responses after epithelial abrasion</article-title><source>Mucosal Immunology</source><volume>10</volume><fpage>1145</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.139</pub-id><pub-id pub-id-type="pmid">28120849</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loveless</surname> <given-names>S</given-names></name><name><surname>Neal</surname> <given-names>JW</given-names></name><name><surname>Howell</surname> <given-names>OW</given-names></name><name><surname>Harding</surname> <given-names>KE</given-names></name><name><surname>Sarkies</surname> <given-names>P</given-names></name><name><surname>Evans</surname> <given-names>R</given-names></name><name><surname>Bevan</surname> <given-names>RJ</given-names></name><name><surname>Hakobyan</surname> <given-names>S</given-names></name><name><surname>Harris</surname> <given-names>CL</given-names></name><name><surname>Robertson</surname> <given-names>NP</given-names></name><name><surname>Morgan</surname> <given-names>BP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis</article-title><source>Brain Pathology</source><volume>28</volume><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1111/bpa.12546</pub-id><pub-id pub-id-type="pmid">28707765</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubbers</surname> <given-names>R</given-names></name><name><surname>van Essen</surname> <given-names>MF</given-names></name><name><surname>van Kooten</surname> <given-names>C</given-names></name><name><surname>Trouw</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Production of complement components by cells of the immune system: production of complement components</article-title><source>Clinical and Experimental Immunology</source><volume>188</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1111/cei.12952</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubinski</surname> <given-names>JM</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Hook</surname> <given-names>L</given-names></name><name><surname>Chang</surname> <given-names>Y</given-names></name><name><surname>Sarver</surname> <given-names>C</given-names></name><name><surname>Mastellos</surname> <given-names>D</given-names></name><name><surname>Lambris</surname> <given-names>JD</given-names></name><name><surname>Cohen</surname> <given-names>GH</given-names></name><name><surname>Eisenberg</surname> <given-names>RJ</given-names></name><name><surname>Friedman</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Herpes simplex virus type 1 evades the effects of antibody and complement in vivo</article-title><source>Journal of Virology</source><volume>76</volume><fpage>9232</fpage><lpage>9241</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.18.9232-9241.2002</pub-id><pub-id pub-id-type="pmid">12186907</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Carreño</surname> <given-names>R</given-names></name><name><surname>Patenia</surname> <given-names>R</given-names></name><name><surname>Tsai</surname> <given-names>KY</given-names></name><name><surname>Xydes-Smith</surname> <given-names>M</given-names></name><name><surname>Alousi</surname> <given-names>AM</given-names></name><name><surname>Champlin</surname> <given-names>RE</given-names></name><name><surname>Sale</surname> <given-names>GE</given-names></name><name><surname>Afshar-Kharghan</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD</article-title><source>Bone Marrow Transplantation</source><volume>49</volume><fpage>972</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1038/bmt.2014.75</pub-id><pub-id pub-id-type="pmid">24777193</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname> <given-names>SJ</given-names></name><name><surname>Mostafa</surname> <given-names>HH</given-names></name><name><surname>Morrison</surname> <given-names>LA</given-names></name><name><surname>Davido</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genome sequence of herpes simplex virus 1 strain McKrae</article-title><source>Journal of Virology</source><volume>86</volume><fpage>9540</fpage><lpage>9541</lpage><pub-id pub-id-type="doi">10.1128/JVI.01469-12</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname> <given-names>KP</given-names></name><name><surname>Hill</surname> <given-names>GR</given-names></name><name><surname>Blazar</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chronic graft-versus-host disease: biological insights from preclinical and clinical studies</article-title><source>Blood</source><volume>129</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-06-686618</pub-id><pub-id pub-id-type="pmid">27821504</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antimicrobial compounds in tears</article-title><source>Experimental Eye Research</source><volume>117</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2013.07.014</pub-id><pub-id pub-id-type="pmid">23880529</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname> <given-names>PL</given-names></name><name><surname>Lee</surname> <given-names>M</given-names></name><name><surname>McGeer</surname> <given-names>EG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A review of human diseases caused or exacerbated by aberrant complement activation</article-title><source>Neurobiology of Aging</source><volume>52</volume><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.12.017</pub-id><pub-id pub-id-type="pmid">28104543</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNearney</surname> <given-names>TA</given-names></name><name><surname>Odell</surname> <given-names>C</given-names></name><name><surname>Holers</surname> <given-names>VM</given-names></name><name><surname>Spear</surname> <given-names>PG</given-names></name><name><surname>Atkinson</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity</article-title><source>Journal of Experimental Medicine</source><volume>166</volume><fpage>1525</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1084/jem.166.5.1525</pub-id><pub-id pub-id-type="pmid">2824652</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menorca</surname> <given-names>RM</given-names></name><name><surname>Fussell</surname> <given-names>TS</given-names></name><name><surname>Elfar</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nerve physiology: mechanisms of injury and recovery</article-title><source>Hand Clinics</source><volume>29</volume><fpage>317</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.hcl.2013.04.002</pub-id><pub-id pub-id-type="pmid">23895713</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moein</surname> <given-names>HR</given-names></name><name><surname>Kheirkhah</surname> <given-names>A</given-names></name><name><surname>Muller</surname> <given-names>RT</given-names></name><name><surname>Cruzat</surname> <given-names>AC</given-names></name><name><surname>Pavan-Langston</surname> <given-names>D</given-names></name><name><surname>Hamrah</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Corneal nerve regeneration after herpes simplex keratitis: a longitudinal in vivo confocal microscopy study</article-title><source>The Ocular Surface</source><volume>16</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2017.12.001</pub-id><pub-id pub-id-type="pmid">29305292</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondino</surname> <given-names>BJ</given-names></name><name><surname>Brady</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Distribution of hemolytic complement in the normal cornea</article-title><source>Archives of Ophthalmology</source><volume>99</volume><fpage>1430</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1001/archopht.1981.03930020304022</pub-id><pub-id pub-id-type="pmid">7020664</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname> <given-names>BP</given-names></name><name><surname>Gasque</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Extrahepatic complement biosynthesis: where<italic>, when and why?</italic></article-title><source>Clinical &amp; Experimental Immunology</source><volume>107</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.1997.d01-890.x</pub-id><pub-id pub-id-type="pmid">9010248</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>LJ</given-names></name><name><surname>Marfurt</surname> <given-names>CF</given-names></name><name><surname>Kruse</surname> <given-names>F</given-names></name><name><surname>Tervo</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Corneal nerves: structure, contents and function</article-title><source>Experimental Eye Research</source><volume>76</volume><fpage>521</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/S0014-4835(03)00050-2</pub-id><pub-id pub-id-type="pmid">12697417</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>RT</given-names></name><name><surname>Pourmirzaie</surname> <given-names>R</given-names></name><name><surname>Pavan-Langston</surname> <given-names>D</given-names></name><name><surname>Cavalcanti</surname> <given-names>BM</given-names></name><name><surname>Aggarwal</surname> <given-names>S</given-names></name><name><surname>Colón</surname> <given-names>C</given-names></name><name><surname>Jamali</surname> <given-names>A</given-names></name><name><surname>Cruzat</surname> <given-names>A</given-names></name><name><surname>Hamrah</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>In vivo confocal microscopy demonstrates bilateral loss of endothelial cells in unilateral herpes simplex keratitis</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>4899</fpage><pub-id pub-id-type="doi">10.1167/iovs.15-16527</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neelam</surname> <given-names>S</given-names></name><name><surname>Mellon</surname> <given-names>J</given-names></name><name><surname>Wilkerson</surname> <given-names>A</given-names></name><name><surname>Niederkorn</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Induction of contrasuppressor cells and loss of immune privilege produced by corneal nerve ablation</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>59</volume><fpage>4738</fpage><lpage>4747</lpage><pub-id pub-id-type="doi">10.1167/iovs.18-24894</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>H</given-names></name><name><surname>Kuril</surname> <given-names>S</given-names></name><name><surname>Bastian</surname> <given-names>D</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Vaena</surname> <given-names>SG</given-names></name><name><surname>Dany</surname> <given-names>M</given-names></name><name><surname>Dai</surname> <given-names>M</given-names></name><name><surname>Heinrichs</surname> <given-names>JL</given-names></name><name><surname>Daenthanasanmak</surname> <given-names>A</given-names></name><name><surname>Iamsawat</surname> <given-names>S</given-names></name><name><surname>Schutt</surname> <given-names>S</given-names></name><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Fairlie</surname> <given-names>DP</given-names></name><name><surname>Atkinson</surname> <given-names>C</given-names></name><name><surname>Ogretmen</surname> <given-names>B</given-names></name><name><surname>Tomlinson</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>X-Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells</article-title><source>JCI Insight</source><volume>3</volume><elocation-id>e121697</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.121697</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>DS</given-names></name><name><surname>Arunakirinathan</surname> <given-names>M</given-names></name><name><surname>Stuart</surname> <given-names>A</given-names></name><name><surname>Angunawela</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Allergic eye disease</article-title><source>BMJ</source><volume>359</volume><elocation-id>j4706</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.j4706</pub-id><pub-id pub-id-type="pmid">29097360</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paun</surname> <given-names>CC</given-names></name><name><surname>Lechanteur</surname> <given-names>YTE</given-names></name><name><surname>Groenewoud</surname> <given-names>JMM</given-names></name><name><surname>Altay</surname> <given-names>L</given-names></name><name><surname>Schick</surname> <given-names>T</given-names></name><name><surname>Daha</surname> <given-names>MR</given-names></name><name><surname>Fauser</surname> <given-names>S</given-names></name><name><surname>Hoyng</surname> <given-names>CB</given-names></name><name><surname>den Hollander</surname> <given-names>AI</given-names></name><name><surname>de Jong</surname> <given-names>EK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A novel complotype combination associates with Age-Related macular degeneration and high complement activation levels in vivo</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>26568</elocation-id><pub-id pub-id-type="doi">10.1038/srep26568</pub-id><pub-id pub-id-type="pmid">27241480</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paunicka</surname> <given-names>KJ</given-names></name><name><surname>Mellon</surname> <given-names>J</given-names></name><name><surname>Robertson</surname> <given-names>D</given-names></name><name><surname>Petroll</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>JR</given-names></name><name><surname>Niederkorn</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye</article-title><source>American Journal of Transplantation</source><volume>15</volume><fpage>1490</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1111/ajt.13240</pub-id><pub-id pub-id-type="pmid">25872977</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname> <given-names>VL</given-names></name><name><surname>Barsam</surname> <given-names>A</given-names></name><name><surname>Duffort</surname> <given-names>S</given-names></name><name><surname>Urbieta</surname> <given-names>M</given-names></name><name><surname>Barreras</surname> <given-names>H</given-names></name><name><surname>Lightbourn</surname> <given-names>C</given-names></name><name><surname>Komanduri</surname> <given-names>KV</given-names></name><name><surname>Levy</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel scoring criteria for the evaluation of ocular Graft-versus-Host disease in a preclinical allogeneic hematopoietic stem cell transplantation animal model</article-title><source>Biology of Blood and Marrow Transplantation</source><volume>22</volume><fpage>1765</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2016.07.012</pub-id><pub-id pub-id-type="pmid">27492793</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittock</surname> <given-names>SJ</given-names></name><name><surname>Lennon</surname> <given-names>VA</given-names></name><name><surname>McKeon</surname> <given-names>A</given-names></name><name><surname>Mandrekar</surname> <given-names>J</given-names></name><name><surname>Weinshenker</surname> <given-names>BG</given-names></name><name><surname>Lucchinetti</surname> <given-names>CF</given-names></name><name><surname>O'Toole</surname> <given-names>O</given-names></name><name><surname>Wingerchuk</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study</article-title><source>The Lancet Neurology</source><volume>12</volume><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70076-0</pub-id><pub-id pub-id-type="pmid">23623397</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proctor</surname> <given-names>LM</given-names></name><name><surname>Strachan</surname> <given-names>AJ</given-names></name><name><surname>Woodruff</surname> <given-names>TM</given-names></name><name><surname>Mahadevan</surname> <given-names>IB</given-names></name><name><surname>Williams</surname> <given-names>HM</given-names></name><name><surname>Shiels</surname> <given-names>IA</given-names></name><name><surname>Taylor</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats</article-title><source>International Immunopharmacology</source><volume>6</volume><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2006.03.002</pub-id><pub-id pub-id-type="pmid">16782534</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaglia</surname> <given-names>V</given-names></name><name><surname>Daha</surname> <given-names>MR</given-names></name><name><surname>Baas</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The complement system in the peripheral nerve: friend or foe?</article-title><source>Molecular Immunology</source><volume>45</volume><fpage>3865</fpage><lpage>3877</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2008.06.018</pub-id><pub-id pub-id-type="pmid">18672287</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname> <given-names>KL</given-names></name><name><surname>Nordestgaard</surname> <given-names>BG</given-names></name><name><surname>Nielsen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complement C3 and risk of diabetic microvascular disease: a cohort study of 95202 individuals from the general population</article-title><source>Clinical Chemistry</source><volume>64</volume><fpage>1113</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2018.287581</pub-id><pub-id pub-id-type="pmid">29523638</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rautemaa</surname> <given-names>R</given-names></name><name><surname>Helander</surname> <given-names>T</given-names></name><name><surname>Meri</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack</article-title><source>Immunology</source><volume>106</volume><fpage>404</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.2002.01421.x</pub-id><pub-id pub-id-type="pmid">12100729</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricklin</surname> <given-names>D</given-names></name><name><surname>Reis</surname> <given-names>ES</given-names></name><name><surname>Lambris</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complement in disease: a defence system turning offensive</article-title><source>Nature Reviews Nephrology</source><volume>12</volume><fpage>383</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2016.70</pub-id><pub-id pub-id-type="pmid">27211870</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricklin</surname> <given-names>D</given-names></name><name><surname>Mastellos</surname> <given-names>DC</given-names></name><name><surname>Reis</surname> <given-names>ES</given-names></name><name><surname>Lambris</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The renaissance of complement therapeutics</article-title><source>Nature Reviews Nephrology</source><volume>14</volume><fpage>26</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2017.156</pub-id><pub-id pub-id-type="pmid">29199277</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosoklija</surname> <given-names>GB</given-names></name><name><surname>Dwork</surname> <given-names>AJ</given-names></name><name><surname>Younger</surname> <given-names>DS</given-names></name><name><surname>Karlikaya</surname> <given-names>G</given-names></name><name><surname>Latov</surname> <given-names>N</given-names></name><name><surname>Hays</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Local activation of the complement system in endoneurial microvessels of diabetic neuropathy</article-title><source>Acta Neuropathologica</source><volume>99</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/PL00007406</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname> <given-names>DJ</given-names></name><name><surname>Zheng</surname> <given-names>M</given-names></name><name><surname>Conrady</surname> <given-names>CD</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Granulocytes in ocular HSV-1 infection: opposing roles of mast cells and neutrophils</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>3763</fpage><pub-id pub-id-type="doi">10.1167/iovs.15-16900</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname> <given-names>DJ</given-names></name><name><surname>Conrady</surname> <given-names>CD</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Herpesvirus-Associated lymphadenitis distorts fibroblastic reticular cell microarchitecture and attenuates CD8 T cell responses to neurotropic infection in mice lacking the STING-IFNα/β defense pathways</article-title><source>The Journal of Immunology</source><volume>197</volume><fpage>2338</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600574</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname> <given-names>DJ</given-names></name><name><surname>Carr</surname> <given-names>MM</given-names></name><name><surname>Gurung</surname> <given-names>HR</given-names></name><name><surname>Halford</surname> <given-names>WP</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The neonatal fc receptor and complement fixation facilitate prophylactic Vaccine-Mediated humoral protection against viral infection in the ocular mucosa</article-title><source>The Journal of Immunology</source><volume>199</volume><fpage>1898</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700316</pub-id><pub-id pub-id-type="pmid">28760885</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname> <given-names>DJ</given-names></name><name><surname>Elliott</surname> <given-names>MH</given-names></name><name><surname>Le</surname> <given-names>YZ</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Corneal epithelial cells exhibit myeloid characteristics and present antigen via MHC class II</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>59</volume><fpage>1512</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1167/iovs.17-23279</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname> <given-names>DJ</given-names></name><name><surname>Hendrix</surname> <given-names>JF</given-names></name><name><surname>Larabee</surname> <given-names>CM</given-names></name><name><surname>Reagan</surname> <given-names>AM</given-names></name><name><surname>Sjoelund</surname> <given-names>VH</given-names></name><name><surname>Robertson</surname> <given-names>DM</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection</article-title><source>Mucosal Immunology</source><volume>12</volume><fpage>827</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1038/s41385-019-0131-y</pub-id><pub-id pub-id-type="pmid">30670763</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname> <given-names>DJ</given-names></name><name><surname>Carr</surname> <given-names>DJJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A STING-dependent innate-sensing pathway mediates resistance to corneal HSV-1 infection via upregulation of the antiviral effector tetherin</article-title><source>Mucosal Immunology</source><volume>9</volume><fpage>1065</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1038/mi.2015.124</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumjanek</surname> <given-names>VM</given-names></name><name><surname>Brent</surname> <given-names>L</given-names></name><name><surname>Pepys</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Cell-mediated immunological responsiveness in mice decomplemented with cobra venom factor</article-title><source>Immunology</source><volume>34</volume><fpage>1117</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">355121</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saban</surname> <given-names>DR</given-names></name><name><surname>Calder</surname> <given-names>V</given-names></name><name><surname>Kuo</surname> <given-names>CH</given-names></name><name><surname>Reyes</surname> <given-names>NJ</given-names></name><name><surname>Dartt</surname> <given-names>DA</given-names></name><name><surname>Ono</surname> <given-names>SJ</given-names></name><name><surname>Niederkorn</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>New twists to an old story: novel concepts in the pathogenesis of allergic eye disease</article-title><source>Current Eye Research</source><volume>38</volume><fpage>317</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.3109/02713683.2012.747617</pub-id><pub-id pub-id-type="pmid">23281793</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacchetti</surname> <given-names>M</given-names></name><name><surname>Lambiase</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Diagnosis and management of neurotrophic keratitis</article-title><source>Clinical Ophthalmology</source><volume>8</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.2147/OPTH.S45921</pub-id><pub-id pub-id-type="pmid">24672223</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacchetti</surname> <given-names>M</given-names></name><name><surname>Lambiase</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neurotrophic factors and corneal nerve regeneration</article-title><source>Neural Regeneration Research</source><volume>12</volume><fpage>1220</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.213534</pub-id><pub-id pub-id-type="pmid">28966630</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheib</surname> <given-names>J</given-names></name><name><surname>Höke</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Advances in peripheral nerve regeneration</article-title><source>Nature Reviews Neurology</source><volume>9</volume><fpage>668</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2013.227</pub-id><pub-id pub-id-type="pmid">24217518</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlereth</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>HS</given-names></name><name><surname>Khandelwal</surname> <given-names>P</given-names></name><name><surname>Saban</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis</article-title><source>The American Journal of Pathology</source><volume>180</volume><fpage>2351</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.015</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seignez</surname> <given-names>A</given-names></name><name><surname>Joly</surname> <given-names>AL</given-names></name><name><surname>Chaumonnot</surname> <given-names>K</given-names></name><name><surname>Hazoumé</surname> <given-names>A</given-names></name><name><surname>Sanka</surname> <given-names>M</given-names></name><name><surname>Marcion</surname> <given-names>G</given-names></name><name><surname>Boudesco</surname> <given-names>C</given-names></name><name><surname>Hammann</surname> <given-names>A</given-names></name><name><surname>Seigneuric</surname> <given-names>R</given-names></name><name><surname>Jégo</surname> <given-names>G</given-names></name><name><surname>Ducoroy</surname> <given-names>P</given-names></name><name><surname>Delarue</surname> <given-names>P</given-names></name><name><surname>Senet</surname> <given-names>P</given-names></name><name><surname>Castilla-Llorente</surname> <given-names>C</given-names></name><name><surname>Solary</surname> <given-names>E</given-names></name><name><surname>Durey</surname> <given-names>MA</given-names></name><name><surname>Rubio</surname> <given-names>MT</given-names></name><name><surname>Hermine</surname> <given-names>O</given-names></name><name><surname>Kohli</surname> <given-names>E</given-names></name><name><surname>Garrido</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease</article-title><source>JCI Insight</source><volume>2</volume><fpage>e90531</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.90531</pub-id><pub-id pub-id-type="pmid">28352659</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyed-Razavi</surname> <given-names>Y</given-names></name><name><surname>Chinnery</surname> <given-names>HR</given-names></name><name><surname>McMenamin</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A novel association between resident tissue macrophages and nerves in the peripheral stroma of the murine cornea</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>55</volume><fpage>1313</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-12995</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shacham-Silverberg</surname> <given-names>V</given-names></name><name><surname>Sar Shalom</surname> <given-names>H</given-names></name><name><surname>Goldner</surname> <given-names>R</given-names></name><name><surname>Golan-Vaishenker</surname> <given-names>Y</given-names></name><name><surname>Gurwicz</surname> <given-names>N</given-names></name><name><surname>Gokhman</surname> <given-names>I</given-names></name><name><surname>Yaron</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phosphatidylserine is a marker for axonal debris engulfment but its exposure can be decoupled from degeneration</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><fpage>1116</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-1155-z</pub-id><pub-id pub-id-type="pmid">30389906</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaheen</surname> <given-names>BS</given-names></name><name><surname>Bakir</surname> <given-names>M</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Corneal nerves in health and disease</article-title><source>Survey of Ophthalmology</source><volume>59</volume><fpage>263</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2013.09.002</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shikari</surname> <given-names>H</given-names></name><name><surname>Antin</surname> <given-names>JH</given-names></name><name><surname>Dana</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ocular graft-versus-host disease: a review</article-title><source>Survey of Ophthalmology</source><volume>58</volume><fpage>233</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2012.08.004</pub-id><pub-id pub-id-type="pmid">23541042</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepp</surname> <given-names>MA</given-names></name><name><surname>Tadvalkar</surname> <given-names>G</given-names></name><name><surname>Hakh</surname> <given-names>R</given-names></name><name><surname>Pal-Ghosh</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Corneal epithelial cells function as surrogate schwann cells for their sensory nerves</article-title><source>Glia</source><volume>65</volume><fpage>851</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1002/glia.23102</pub-id><pub-id pub-id-type="pmid">27878997</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strainic</surname> <given-names>MG</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>D</given-names></name><name><surname>An</surname> <given-names>F</given-names></name><name><surname>Lalli</surname> <given-names>PN</given-names></name><name><surname>Muqim</surname> <given-names>N</given-names></name><name><surname>Shapiro</surname> <given-names>VS</given-names></name><name><surname>Dubyak</surname> <given-names>GR</given-names></name><name><surname>Heeger</surname> <given-names>PS</given-names></name><name><surname>Medof</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells</article-title><source>Immunity</source><volume>28</volume><fpage>425</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.001</pub-id><pub-id pub-id-type="pmid">18328742</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streilein</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ocular immune privilege: therapeutic opportunities from an experiment of nature</article-title><source>Nature Reviews Immunology</source><volume>3</volume><fpage>879</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1038/nri1224</pub-id><pub-id pub-id-type="pmid">14668804</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Susuki</surname> <given-names>K</given-names></name><name><surname>Rasband</surname> <given-names>MN</given-names></name><name><surname>Tohyama</surname> <given-names>K</given-names></name><name><surname>Koibuchi</surname> <given-names>K</given-names></name><name><surname>Okamoto</surname> <given-names>S</given-names></name><name><surname>Funakoshi</surname> <given-names>K</given-names></name><name><surname>Hirata</surname> <given-names>K</given-names></name><name><surname>Baba</surname> <given-names>H</given-names></name><name><surname>Yuki</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>3956</fpage><lpage>3967</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4401-06.2007</pub-id><pub-id pub-id-type="pmid">17428969</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Hendricks</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Interferon gamma regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas</article-title><source>Journal of Experimental Medicine</source><volume>184</volume><fpage>1435</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1084/jem.184.4.1435</pub-id><pub-id pub-id-type="pmid">8879215</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>AW</given-names></name><name><surname>Ng</surname> <given-names>TF</given-names></name><name><surname>Tf</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Negative regulators that mediate ocular immune privilege</article-title><source>Journal of Leukocyte Biology</source><volume>103</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1002/JLB.3MIR0817-337R</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tegla</surname> <given-names>CA</given-names></name><name><surname>Cudrici</surname> <given-names>C</given-names></name><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Trippe</surname> <given-names>R</given-names></name><name><surname>Rus</surname> <given-names>V</given-names></name><name><surname>Niculescu</surname> <given-names>F</given-names></name><name><surname>Rus</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Membrane attack by complement: the assembly and biology of terminal complement complexes</article-title><source>Immunologic Research</source><volume>51</volume><fpage>45</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s12026-011-8239-5</pub-id><pub-id pub-id-type="pmid">21850539</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenner</surname> <given-names>AJ</given-names></name><name><surname>Stevens</surname> <given-names>B</given-names></name><name><surname>Woodruff</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New tricks for an ancient system: Physiological and pathological roles of complement in the CNS</article-title><source>Molecular Immunology</source><volume>102</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2018.06.264</pub-id><pub-id pub-id-type="pmid">29958698</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepelus</surname> <given-names>TC</given-names></name><name><surname>Chiu</surname> <given-names>GB</given-names></name><name><surname>Maram</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Chopra</surname> <given-names>V</given-names></name><name><surname>Sadda</surname> <given-names>SR</given-names></name><name><surname>Lee</surname> <given-names>OL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Corneal features in ocular graft-versus-host disease by in vivo confocal microscopy</article-title><source>Graefe's Archive for Clinical and Experimental Ophthalmology</source><volume>255</volume><fpage>2389</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1007/s00417-017-3759-x</pub-id><pub-id pub-id-type="pmid">28875340</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname> <given-names>S</given-names></name><name><surname>Thurman</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue-targeted complement therapeutics</article-title><source>Molecular Immunology</source><volume>102</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2018.06.005</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triantafilou</surname> <given-names>K</given-names></name><name><surname>Hughes</surname> <given-names>TR</given-names></name><name><surname>Triantafilou</surname> <given-names>M</given-names></name><name><surname>Morgan</surname> <given-names>BP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>2903</fpage><lpage>2913</lpage><pub-id pub-id-type="doi">10.1242/jcs.124388</pub-id><pub-id pub-id-type="pmid">23613465</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhagen</surname> <given-names>C</given-names></name><name><surname>Breebaart</surname> <given-names>AC</given-names></name><name><surname>Kijlstra</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The effects of complement depletion on corneal inflammation in rats</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>33</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">1740355</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verschoor</surname> <given-names>A</given-names></name><name><surname>Brockman</surname> <given-names>MA</given-names></name><name><surname>Knipe</surname> <given-names>DM</given-names></name><name><surname>Carroll</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection</article-title><source>The Journal of Immunology</source><volume>167</volume><fpage>2446</fpage><lpage>2451</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.5.2446</pub-id><pub-id pub-id-type="pmid">11509581</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viney</surname> <given-names>JL</given-names></name><name><surname>Dianda</surname> <given-names>L</given-names></name><name><surname>Roberts</surname> <given-names>SJ</given-names></name><name><surname>Wen</surname> <given-names>L</given-names></name><name><surname>Mallick</surname> <given-names>CA</given-names></name><name><surname>Hayday</surname> <given-names>AC</given-names></name><name><surname>Owen</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Lymphocyte proliferation in mice congenitally deficient in T-cell receptor alpha beta + cells</article-title><source>PNAS</source><volume>91</volume><fpage>11948</fpage><lpage>11952</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.25.11948</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname> <given-names>CW</given-names></name><name><surname>Fritzinger</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cobra venom factor: structure, function, and humanization for therapeutic complement depletion</article-title><source>Toxicon</source><volume>56</volume><fpage>1198</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.04.007</pub-id><pub-id pub-id-type="pmid">20417224</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname> <given-names>G</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Reed</surname> <given-names>A</given-names></name><name><surname>Babra</surname> <given-names>B</given-names></name><name><surname>Putman</surname> <given-names>T</given-names></name><name><surname>Wick</surname> <given-names>E</given-names></name><name><surname>Wechsler</surname> <given-names>SL</given-names></name><name><surname>Rohrmann</surname> <given-names>GF</given-names></name><name><surname>Jin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sequence and comparative analysis of the genome of HSV-1 strain McKrae</article-title><source>Virology</source><volume>433</volume><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2012.08.043</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname> <given-names>EE</given-names></name><name><surname>Kolev</surname> <given-names>M</given-names></name><name><surname>Kemper</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complement and the regulation of T cell responses</article-title><source>Annual Review of Immunology</source><volume>36</volume><fpage>309</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053245</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willcox</surname> <given-names>MD</given-names></name><name><surname>Morris</surname> <given-names>CA</given-names></name><name><surname>Thakur</surname> <given-names>A</given-names></name><name><surname>Sack</surname> <given-names>RA</given-names></name><name><surname>Wickson</surname> <given-names>J</given-names></name><name><surname>Boey</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Complement and complement regulatory proteins in human tears</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>38</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9008624</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Xie</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Saunders</surname> <given-names>TL</given-names></name><name><surname>Fox</surname> <given-names>DA</given-names></name><name><surname>Rosenquist</surname> <given-names>R</given-names></name><name><surname>Lin</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of complement in a rat model of Paclitaxel-Induced peripheral neuropathy</article-title><source>The Journal of Immunology</source><volume>200</volume><fpage>4094</fpage><lpage>4101</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701716</pub-id><pub-id pub-id-type="pmid">29695418</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>FS</given-names></name><name><surname>Yin</surname> <given-names>J</given-names></name><name><surname>Lee</surname> <given-names>P</given-names></name><name><surname>Hwang</surname> <given-names>FS</given-names></name><name><surname>McDermott</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sensory nerve regeneration after epithelium wounding in normal and diabetic cornea</article-title><source>Expert Review of Ophthalmology</source><volume>10</volume><fpage>383</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1586/17469899.2015.1049157</pub-id><pub-id pub-id-type="pmid">28446923</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname> <given-names>H</given-names></name><name><surname>Rowe</surname> <given-names>AM</given-names></name><name><surname>Lathrop</surname> <given-names>KL</given-names></name><name><surname>Harvey</surname> <given-names>SA</given-names></name><name><surname>Hendricks</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis</article-title><source>Journal of Virology</source><volume>88</volume><fpage>7870</fpage><lpage>7880</lpage><pub-id pub-id-type="doi">10.1128/JVI.01146-14</pub-id><pub-id pub-id-type="pmid">24789786</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname> <given-names>TS</given-names></name><name><surname>Zaidi</surname> <given-names>T</given-names></name><name><surname>Pier</surname> <given-names>GB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Role of neutrophils, myd88-mediated neutrophil recruitment, and complement in antibody-mediated defense against <italic>pseudomonas aeruginosa</italic> keratitis</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>51</volume><fpage>2085</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1167/iovs.09-4139</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Köhl</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A complex role for complement in allergic asthma</article-title><source>Expert Review of Clinical Immunology</source><volume>6</volume><fpage>269</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1586/eci.09.84</pub-id><pub-id pub-id-type="pmid">20402389</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48378.023</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Chiu</surname><given-names>Isaac M</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Gadjeva</surname><given-names>Mihaela</given-names> </name><role>Reviewer</role><aff><institution>Brigham and Women's Hospital</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Suvas</surname><given-names>Susmit</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Complement and CD4<sup>+</sup> T cells drive context-specific corneal sensory neuropathy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Mihaela Gadjeva (Reviewer #2); Susmit Suvas (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this interesting study, Derek et al. showed the involvement of complement C3 in causing corneal sensory neuropathy in mouse models of HSV keratitis, T-dependent allergic eye disease, and ocular graft-versus-host disease (GVHD). They find that complement C3 plays a key role in nerve damage during HSV-1 induced ocular keratitis, as well as in a mouse model of GVHD. They also find that T cells played a role in both disease conditions, and in particular CD4 T cells. Local depletion of C3 by cobra venom factor or the use of C3<sup>-/-</sup> mice in these two models of chronic ocular inflammation prevented the loss of corneal sensation. The authors also showed that adoptive transfer of purified splenic CD4<sup>+</sup> or CD8<sup>+</sup> T cells from HSV-1 infected mice into TCRa<sup>-/-</sup> mice documented the involvement of CD4 but not CD8 expressing T cells in causing the loss of corneal sensation after ocular HSV-1 infection. Together, these studies confirm the involvement of C3 and CD4 expressing T cells in causing the loss of corneal sensation in two major mouse models of chronic ocular inflammation. Therefore, these findings uncover immune mechanisms of nerve damage in several important eye inflammation contexts, and has interesting clinical implications for major conditions for patients that suffer from HSV1 and GVHD. All three reviewers agreed that this is a nice study and worthy of publication. However, there is a need to address some points and concerns raised below.</p><p>Essential revisions:</p><p>1) What is the relationship between C3 and T cells in HSV1 induced neuropathy? Figure 1F does not convincingly show equal (or decreased) influx of CD3+ T cells in HSV1 infected corneas from B6 and C3<sup>-/-</sup> mice. There is a need to prove this by a more quantitative approach either by imaging or by flow cytometry.</p><p>2) The authors did not address potential non-specific effects of CVF while administering into infected corneas. Does it affect T cell survival or influx in HSV infected corneas?</p><p>3) Does CVF treatment decrease local T cell recruitment in the GVHD model? Figure 8E seems to indicate this, but can the authors quantify this by immunostaining or flow cytometry?</p><p>4) The baseline role for T cells in mediating HSV1 induced pain and neuropathy is not complete prior to adoptive transfers. In the HSV1 model, how do WT mice compare with TCRa<sup>-/-</sup> mice for corneal sensation loss in the Cochet-Bonnet score? Is there less nerve damage in TCRa<sup>-/-</sup> mice?</p><p>5) In Figure 3B, can the authors show the full time course of the corneal sensation threshold between WT vs. OT-II transfer data?</p><p>6) Generally, is the decrease in neuronal fibers associated with loss of neuronal cells in the TGs?</p><p>7) In view of recent work describing the importance of intracellular complement for T cell functionality, authors should interrogate the importance of intracellular complement synthesis and/or T cell activation in the models (Hansen et al., 2019; West et al., 2018). Indeed, authors show RT-PCR data from day 3 sorted cells from mice infected with HSV corneas, however, the dominant T-cell mediated effect seems to occur at later time points, suggestive a possible contribution of endogenous T-cell derived complement. Can the authors address this possibility?</p><p>8) If C3 is predominant factor in causing the loss of corneal sensation in these models, what is the possible underlying mechanism?</p><p>9) Can authors comment on the potential mechanisms of neuronal fiber retractions?</p><p>10) The use of CVF treatment offers a traditional approach to reduce complement activation. Given the developed therapies that target C5aR-signaling, authors should comment on the use of anti-C5a biologics for complement blockade in view of their discussion on potential therapies.</p><p>11) What possible factors from effector CD4 T cells are involved in activating C3 in GVHD and keratitis model?</p><p>12) While AED seems to be a contrasting model, the authors find lack of sensory phenotypes and nerve loss in this model (Figure 6). Therefore, we do not think this is a good model as comparison. The limitations of comparing this vs. the other models should be Discussed.</p><p>13) In Figure 1, it's interesting that while HSV-1 titers go up in the tear film and trigeminal ganglia (TG) at days 5 and 7 in C3<sup>-/-</sup> mice compared to WT mice, HSV titers are not elevated in the C3<sup>-/-</sup> cornea compared to WT mice. It's possible that the reason viral burdens are similar between WT and c3<sup>-/-</sup> cornea is that a large number of nerve fibers and keratinocytes are destroyed that harbor the virus in WT mice. Could the authors address this point in the Discussion?</p><p>14) References: The authors can cite additional papers relevant to HSV-1 and complement C3: This includes the papers by Carroll and Knipe showing myeloid immune cell derived complement plays a role in HSV-1 host defense in peripheral tissues (Verschoor et al., 2001; Gadjeva et al., J Immunol. 2002 PMID: 12421924; Verschoor et al., J Immunol 2003 PMID:14607939) and papers showing that HSV-1 inhibits complement through glycoprotein C to evade host defense (Hook et al., J Virol 2006 PMID: 16571820; Lubinski et al., 2002)</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48378.024</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) What is the relationship between C3 and T cells in HSV1 induced neuropathy? Figure 1F does not convincingly show equal (or decreased) influx of CD3+ T cells in HSV1 infected corneas from B6 and C3<sup>-/-</sup> mice. There is a need to prove this by a more quantitative approach either by imaging or by flow cytometry.</p></disp-quote><p>We performed additional experiments to quantitatively assess T cell in the corneas of WT and C3<sup>-/-</sup> mice by flow cytometry. These data show no difference in CD4 or CD8 T cell infiltration at day 7 post-infection(Figure 1G).</p><p>Briefly, the relationship between C3 and T cells is likely an indirect, coordinated process. Please see our working hypothesis for the underlying pathomechanism in critique #8 below.</p><disp-quote content-type="editor-comment"><p>2) The authors did not address potential non-specific effects of CVF while administering into infected corneas. Does it affect T cell survival or influx in HSV infected corneas?</p></disp-quote><p>Pharmacologic information about CVF is now included in the Discussion to clarify the mechanism of action and potential side effects. Briefly, CVF is generally nontoxic. While it has been used experimentally for several decades, there is little substantive evidence that it directly impacts the physiology of T cells. Please see Discussion paragraphs nine and ten for more information.</p><p>CVF treatment leads to a ~50% reduction in cornea-infiltrating CD4 T cells compared to the vehicle control group (Figure 5G). This is consistent with the observation that CVF treatment also reduces corneal inflammation/edema (Figure 5D).</p><p>CVF treatment had no discernable impact on T cell expansion in the draining lymph nodes or numbers in peripheral circulation (Figure 5—figure supplement 2). Taken together, this suggests that CVF does not alter T cell survival.</p><disp-quote content-type="editor-comment"><p>3) Does CVF treatment decrease local T cell recruitment in the GVHD model? Figure 8E seems to indicate this, but can the authors quantify this by immunostaining or flow cytometry?</p></disp-quote><p>T cell numbers and nerve densities were quantified from confocal images of cornea flat mounts using Imaris software (AED and GVHD models). These data are now included in Figures 6, 7, and 8.</p><p>Briefly, no differences were found in the numbers of CD3<sup>+</sup> cells in the central corneas of CVF vs. PBS treated mice in the GHVD model at the experiment endpoint (Figure 8H). Given the protracted treatment regimen, this suggests that CVF likely has no impact on T cell survival (relevant to critique # 2 above).</p><p>Our data does not exclude the possibility that CVF treatment may delay T cell influx. However, the Perez laboratory is currently investigating T cell response dynamics in the progression of ocular GVHD.</p><disp-quote content-type="editor-comment"><p>4) The baseline role for T cells in mediating HSV1 induced pain and neuropathy is not complete prior to adoptive transfers. In the HSV1 model, how do WT mice compare with TCRa<sup>-/-</sup> mice for corneal sensation loss in the Cochet-Bonnet score? Is there less nerve damage in TCRa<sup>-/-</sup> mice?</p></disp-quote><p>Cochet-Bonnet scores for corneal sensation are highly reproducible direct measurements (data are not relative/normalized). As shown in the original manuscript, sensation loss was not observed in TCRα<sup>-/-</sup> mice without addition of exogenous T cells.</p><p>Corneal nerve imaging was not performed on corneas from TCRα<sup>-/-</sup> mice, but the sensation data underscore that HSV-associated sensation loss is T cell-dependent.</p><p>The initial time (day post-infection) at which sensation is ‘significantly’ reduced relative to the corresponding control lags by one day in the adoptive transfer model compared to WT mice. This corresponds with the relative lymphopenic status of the TCRα<sup>-/-</sup> mice following adoptive transfer compared to WT mice, which have more than 10 times as many T cells in the cornea-draining lymph nodes at day 8 post-infection (compare Figure 2B and Figure 2—figure supplement 1A). However, the tempo of sensation loss is consistent between models once instigated by HSV-1 infection.</p><p>From a gross pathology standpoint, corneas from TCRα<sup>-/-</sup> control mice generally remained transparent following HSV-1 infection. However, corneal opacification was observed in HSV-1-infected TCRα<sup>-/-</sup> mice reconstituted with exogenous T cells (data not shown). These observations parallel those from the Hendricks lab showing a reduction in corneal opacification when mice are depleted of CD4 T cells (Yun et al., 2014).</p><disp-quote content-type="editor-comment"><p>5) In Figure 3B, can the authors show the full time course of the corneal sensation threshold between WT vs. OT-II transfer data?</p></disp-quote><p>Baseline sensation and control data are now included in Figure 3B and Figure 3—figure supplement 2.</p><p>These experiments were performed to determine the necessity of antigen-specific T cells in driving sensation loss after the tempo of corneal sensation loss had been established (Figure 1B and Figure 3A). Accordingly, corneal sensation data were only measured at baseline and day 7 post-infection for the experiments involving OT-II mice and cells.</p><disp-quote content-type="editor-comment"><p>6) Generally, is the decrease in neuronal fibers associated with loss of neuronal cells in the TGs?</p></disp-quote><p>The cell bodies of the corneal nerves are housed within the trigeminal ganglion. Accordingly, addressing these related issues would require meticulous nerve tracing studies well beyond the scope of the current manuscript.</p><p>The current investigation specifically addresses immune-mediated mechanisms of corneal sensation loss using murine models of clinically-relevant ocular surface inflammatory diseases. While certainly important, the individual fates of damaged corneal sensory nerves, were not explored.</p><p>The revised Discussion includes a brief synopsis of the relevant literature:</p><p>“…the individual fates of damaged corneal nerves were not explored herein. Lessons from peripheral nerve injury in other settings indicate that some damaged nerves undergo apoptosis, yet effectively promoting functional regeneration of surviving neurons remains a major clinical hurtle… Likewise, promoting functional regeneration of damaged corneal nerves is important for restoration of immune privilege and ocular surface health.”</p><disp-quote content-type="editor-comment"><p>7) In view of recent work describing the importance of intracellular complement for T cell functionality, authors should interrogate the importance of intracellular complement synthesis and/or T cell activation in the models (Hansen et al., 2019; West et al., 2018). Indeed, authors show RT-PCR data from day 3 sorted cells from mice infected with HSV corneas, however, the dominant T-cell mediated effect seems to occur at later time points, suggestive a possible contribution of endogenous T-cell derived complement. Can the authors address this possibility?</p></disp-quote><p>Intracellular complement function is intriguing and certainly noteworthy. However, this area remains somewhat controversial within the complement field (discussed extensively at the 2018 International Complement Workshop in Santa Fe, NM).</p><p>The revised manuscript Discussion includes citations for the following landmark studies, and the pertinent findings are outlined below:</p><p>a) Claudia Kemper’s lab indicates that murine CD4 T cells lacking C3 have reduced Th1 responses (IFNγ) following in vitroexpansion and re-stimulation (Sup. Figure 4I in Liszewski et al., 2013).</p><p>– This paper’s primary finding is that C3a may have a critical survival function on <italic>human</italic> T cells, but this has not been recapitulated in mice.</p><p>– Similarly,Th1 responses are reduced in C3-deficient human T cells following in vitro stimulation (PMID: 24321396).</p><p>b) Peter Garred’s lab utilized human donor cells and found that C3 product/receptor expression were <italic>downregulated</italic> in T cells activated in vitro. They conclude that “endogenous[ly] expressed C3 is <italic>not</italic> vital for T cell turnover” (Hansen et al., 2019).</p><p>c) John Atkinson’s lab has shown that human CD4 T cells acquire C3 from the extracellular environment, but exogenous C3 did not alter IFNγ production upon activation in vitro (Elvington et al., 2017).</p><p>Importantly, the studies cited above investigate Th1 responses in human T cells with anti-CD3 and anti-CD46 stimulation in vitro. There are species-specific differences in complement biology between humans and mice:</p><p>a) While CD46 is required for Th1 polarization/cytokine production in human T cells, mice do not express CD46.</p><p>b) Instead, data from the Medof lab indicate that anaphylatoxin receptors are important for Th1 cytokine production in mice (Strainic et al., 2008).</p><p>In light of the studies listed above, we addressed several specific questions relative to C3 and T cell function using the HSV-1 ocular infection model as a way to prime T cells <underline>in vivo</underline>.</p><p>a) Our data show no difference in IFNγ production in T cells from C3<sup>-/-</sup> and WT mice following in vivo priming by way of ocular HSV-1 infection (Figure 2C). This was determined using a PMA/ionomycin-based re-stimulation assay comparable to that used in the studies cited above.</p><p>b) Our data show that endogenous C3 production is not required for T cell functionality in mice. This is based on the ability of sorted C3<sup>-/-</sup> T cells to mediate corneal sensation loss upon transfer into TCRα<sup>-/-</sup> mice (Figure 2D).</p><p>c) The cornea contains high concentrations of C3 protein (Figure 5B) prior to T cell infiltration. Accordingly, there is little evidence that putative C3 production by murine T cells specifically tips the balance in favor of pathology.</p><p>d) It remains possible that anaphylatoxin receptor signaling from locally produced C3a (and potentially C5a generated downstream) modulates T cell effector function upon extravasation into the inflammatory milieu. However, anaphylatoxin receptor signaling was not investigated herein.</p><p>Finally, C3 breakdown products may lower the threshold for T cell activation/effector function through costimulatory pathways (e.g. CD46, C3aR1) akin to what has been shown for B cell responses through CD21 (PMID: 18328742, 30305631, 11418645, 25210145).</p><p>a) The clinical phenotype in the C3<sup>-/-</sup> human population, albeit rare, involves high susceptibility to bacterial infections and immune complex-mediated diseases. However, published evidence suggesting that C3<sup>-/-</sup> patients are more susceptible to viral infections is conspicuously absent (PMID: 16499568, 31192812, 18802120).</p><p>b) If a profound Th1 deficit existed in C3<sup>-/-</sup> patients, their clinical phenotype would almost certainly include maladaptive responses to viral infections with increased morbidity.</p><p>c) Importantly, C3b and C4b are both ligands for CD46, thus C4b may compensate for the absence of C3b to facilitate Th1 induction in C3-deficient patients in vivo.</p><disp-quote content-type="editor-comment"><p>8) If C3 is predominant factor in causing the loss of corneal sensation in these models, what is the possible underlying mechanism?</p></disp-quote><p>The revised discussion now outlines a working hypothesis for the <underline>possible</underline> mechanism of corneal sensation loss (Discussion paragraph seven). This framework is a context-specific process involving C3 and CD4 T cells and is supported by established findings:</p><p>a) Corneal inflammation favors local activation of the complement pathway.</p><p>b) Sensory nerve terminals are damaged by sublytic MAC formation downstream of C3 activation (PMID: 21850539).</p><p>c) Cytokines produced by CD4 T cells (Th1) activate phagocytes (professional and nonprofessional) to consume damaged sensory nerve fibers.</p><p>d) Local complement activation may also augment Th1 cytokine secretion upon extravasation into the cornea via anaphlatoxin receptor signaling (PMID: 18328742).</p><p>The relevant complement pathways (classical, alternative, lectin, MAC-involvement), cellular targets, and the impact of anaphylatoxin receptor signaling are all topics of future investigation. By addressing the ‘heart’ of the complement pathway (C3), this study opens the door to future investigations to further elucidate the relevant pathomechanisms and corresponding therapeutic targets.</p><disp-quote content-type="editor-comment"><p>9) Can authors comment on the potential mechanisms of neuronal fiber retractions?</p></disp-quote><p>The nerve-intrinsic mechanism underlying sensory fiber retraction has not been clearly established for any corneal pathology to date. In line with the mechanism outlined above (critique #8), we hypothesize that membrane attack complex deposition on sensory fibers leads to damage and clearance. This is described in the revised manuscript:</p><p>“[An] imbalance in ‘complement proteostasis’ may favor deposition of complement fragments and sublytic MAC on corneal sensory nerve fibers (Tegla et al., 2011; Triantafilou et al., 2013). Notwithstanding, the nerve-intrinsic molecular mechanisms responsible for trigeminal sensory fiber retraction, neuronal death, or axonal regeneration in the cornea are largely unknown Stepp et al., 2017).”</p><p>Also, please see response to critique #6.</p><disp-quote content-type="editor-comment"><p>10) The use of CVF treatment offers a traditional approach to reduce complement activation. Given the developed therapies that target C5aR-signaling, authors should comment on the use of anti-C5a biologics for complement blockade in view of their discussion on potential therapies.</p></disp-quote><p>CVF was used merely as an experimental proof of concept. Subsequent studies are needed to investigate each complement initiation pathway, other effectors, and anaphylatoxin receptors.</p><p>Please see the “complement drug development pipeline” graphic featured in Ricklin et al., 2018.</p><p>There are many complement-targeted therapeutics in pre-clinical development or clinical trials (see the “complement drug development pipeline” graphic featured in Ricklin et al., 2018). The anti-C5 antibody Eculizumab is perhaps the most successful of the approved complement therapeutics, but its effect on C5aR signaling is indirect. In light of the numerous complement targets and concordant drugs in preclinical development, a particular focus on C5aR-signaling is hard to justify in the discussion, as our paper does not address C5 directly.</p><disp-quote content-type="editor-comment"><p>11) What possible factors from effector CD4 T cells are involved in activating C3 in GVHD and keratitis model?</p></disp-quote><p>Please see response to critique #8 above.</p><p>CD4 T cells are not required for C3 activation in the cornea. Our hypothesis is that T cell cytokines activate phagocytes to clear complement-tagged sensory nerve fibers.</p><p>This topic has been addressed in the revised Discussion:</p><p>“AED is driven primarily by a combined Th2/Th17 CD4 T cell response that differs from the Th1 bias observed in HSV-1 keratitis and ocular GHVD. This suggests that Th1 cytokines such as IFNγ, IL-2, and lymphotoxin-α may be important in coordinating corneal sensation loss.”</p><disp-quote content-type="editor-comment"><p>12) While AED seems to be a contrasting model, the authors find lack of sensory phenotypes and nerve loss in this model (Figure 6). Therefore, we do not think this is a good model as comparison. The limitations of comparing this vs. the other models should be Discussed.</p></disp-quote><p>Differences in CD4 T cell polarization among the models are now clearly highlighted in the Discussion (please see response 11).</p><p>To further address this point, we have added the following to the Discussion:</p><p>“The lack of sensory phenotype in the AED model was unanticipated, given that patients with severe allergy have been shown to have changes in nerve morphology… This contrasting model underscores the context-dependency of sensation loss during corneal inflammation.”</p><disp-quote content-type="editor-comment"><p>13) In Figure 1, it's interesting that while HSV-1 titers go up in the tear film and trigeminal ganglia (TG) at days 5 and 7 in C3<sup>-/-</sup> mice compared to WT mice, HSV titers are not elevated in the C3<sup>-/-</sup> cornea compared to WT mice. It's possible that the reason viral burdens are similar between WT and c3<sup>-/-</sup> cornea is that a large number of nerve fibers and keratinocytes are destroyed that harbor the virus in WT mice. Could the authors address this point in the Discussion?</p></disp-quote><p>This topic has been addressed in the revised discussion in parallel with a commentary on the impact of HSV-1 glycoprotein C (Discussion section paragraph four).</p><p>Briefly, it is likely that the potent antiviral type-1 interferon response protects the cornea against excessive HSV-1 replication even in the absence of C3. Accordingly, the maintenance of corneal innervation in C3<sup>-/-</sup> mice may enhance shedding of virus produced within the TG.</p><disp-quote content-type="editor-comment"><p>14) References: The authors can cite additional papers relevant to HSV-1 and complement C3: This includes the papers by Carroll and Knipe showing myeloid immune cell derived complement plays a role in HSV-1 host defense in peripheral tissues (Verschoor et al.,, 2001; Gadjeva et al., J Immunol. 2002 PMID: 12421924; Verschoor et al., J Immunol 2003 PMID:14607939) and papers showing that HSV-1 inhibits complement through glycoprotein C to evade host defense (Hook et al., J Virol 2006 PMID: 16571820; Lubinski et al., 2002)</p></disp-quote><p>In our model, corneal nerve damage occurs prior to generation of broad humoral immunity to HSV-1. The Carroll and Knipe papers cited above show the impact of bone marrow-derived complement on <italic>induction</italic> of humoral immunity to HSV-1, but they do not address host defense with respect to viral pathogenesis or tissue damage. The papers are solid, but their relationship to the current investigation is debatable.</p><p>However, the revised manuscript cites the Verschoor et al. paper (PMID: 11509581) as evidence of macrophage-derived C3 production and a 1999 <italic>PNAS</italic> paper from Knipe and Carroll corroborating normal proliferation of WT and C3<sup>-/-</sup> T cells primed by vaccination with a replication defective virus based on [<sup>3</sup>H]thymidine uptake in response to viral antigen re-stimulation (PMID: 10535987).</p><p>The topic of glycoprotein C (gC) and complement evasion are now addressed in the Discussion (paragraph four).</p></body></sub-article></article>